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PLASMODIUM FALCIPARUM LIFE CYCLE 
Malaria is one of the leading infectious diseases in the world, with at least 300-500 million 
clinical cases and 1-3 million deaths each year, mostly in children under the age of five [1, 
2]. Malaria has a tremendous impact on the quality of life [3] and estimates indicate the 
disease burden is approaching 50 million disability-adjusted life years [4]. Furthermore, the 
economic growth reduction due to malaria can be 1.3% per year, which contributes 
significantly to the ongoing poverty in endemic countries [5].  
 
Malaria is caused by single-cell (protozoan) parasites of the genus Plasmodium. Four 
species can cause human disease: P. falciparum, P. vivax, P. ovale and P. malariae. P. 
falciparum is the most dangerous malaria parasite species for humans and is responsible for 
the large number of casualties. The life cycle of P. falciparum is complicated with 
development both in the human host and the mosquito vector (figure 1.1). When an infected 
female mosquito takes a blood meal, sporozoites are injected into the human host together 
with the saliva, resulting in a malaria infection. After asexual development in the liver, cyclic 
proliferation of asexual parasites is maintained in the red blood cells. Some of these asexual 
parasites develop into male and female gametocytes that, when ingested by a female 
mosquito, fertilize and finally 
complete the life cycle by 
producing sporozoites in the 
mosquito salivary glands. 
During infection, both asexual 
and sexual forms of the 
parasite can circulate in the 
bloodstream of infected 
persons. Clinical disease is 
caused by proliferation of 
asexual forms in the patient’s 
red blood cells while the 
gametocytes do not directly 
cause disease symptoms but 
are essential for transmission 
of the disease and spread of 
parasites in the population [6]. 
 
 
 
Figure 1.1: Plasmodium life cycle 
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PLASMODIUM FALCIPARUM GAMETOCYTE DEVELOPMENT 
Plasmodium falciparum gametocytes follow a developmental process of five different stages 
(I-V) to maturation [7]. All five stages can be observed in parasites from in vitro culture [8, 9] 
(figure 1.2) but in the circulation only stage V gametocytes can be observed since the 
immature stages I-IV sequester from the bloodstream. The first gametocyte stage cannot be 
distinguished from young asexual stages; morphological changes start from the second 
gametocyte stage and morphological differences between male and female gametocytes are 
clearly visible from stage III gametocytes onwards [8]. The drastic changes in morphology 
are preceded by a series of changes on the molecular and biochemical level, with a broad 
array of genes expressed in a sexual stage-specific way at the RNA or the protein level [10-
18]. Although the study of sexual stage-specific expression patterns has not yet elucidated 
the signals for commitment to sexual stage development or for sex determination, it certainly 
increased knowledge about sexual stage development. Sexual stage development starts in 
the asexual cycle preceding morphological changes of the gametocyte with the expression 
of Pfs16 mRNA as the earliest marker of parasite commitment to sexual stage development 
[19, 20]. Schizonts that are committed to develop into sexual stage parasites will produce 
either all male or all female gametocytes [21, 22]. 
 
The model describing the sexual stage development of Plasmodium falciparum parasites 
[23] is similar to that of other parasites of the suborder Haemospororina (phylum 
Apicomplexa, subclass Coccidiasina). However, except for Plasmodium, all parasites from 
the Haemospororina (Haemoproteus, Hepatocystis and Leucocytozoon species) form 
gametocytes directly from the asexual parasites that arise from the exo-erythrocytic 
schizonts without additional asexual replication. This suggests that sexual development is 
genetically determined in all Haemospororina species. The multiple or even indefinite rounds 
of asexual multiplication in red blood cells make Plasmodium a rather odd parasite in this 
group. Sexual development can therefore be influenced by other factors than genetics in 
Plasmodium resulting in regulation of sexual stage development [23].  
 
Studies based on standard procedures have shown that P. falciparum gametocytes are 
present in a relatively low proportion of infected individuals and gametocyte densities are in 
general low [6]. Possible explanations for the low gametocyte production are often based on 
the evolutionary principle that there should be a balance between asexual replication 
(virulence) and production of sexual stages (transmission) [13, 23, 24]. It has been 
suggested that asexual multiplication is a mechanism to prolong the time of potential 
transmission during an infection [25]. Sexual reproduction can lead to recombination if 
multiple clones are present, subsequently increasing genetic variability. This may be of 
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benefit for the parasites as it may enhance survival in changing habitats and unfavourable 
mutations will not accumulate. 
Considering the evolutionary rule that fitness should be optimised in combination with other 
parasites from the same suborder that do rely much more on sexual stage development, it 
remains a question why P. falciparum produces relatively small numbers of transmission 
stages. Additionally we may question how transmission of the disease can be so efficient 
despite the relatively low production of transmission stages. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Development of sexual stage Plasmodium falciparum parasites from in vitro culture after 
synchronisation. (A) gametocytes stage I (B) gametocytes stage IIA (C) stage IIB (D) stage III (E) stage IV (F) 
stage VA (G) stage VB (H) female gamete and exflagellating male parasite [9]. 
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MALARIA CONTROL AND TRANSMISSION 
Control of malaria has proven to be a difficult task. Despite intense control efforts, the 
disease remains endemic in many parts of the world. Moreover, malaria mortality is 
increasing due to lack of an effective vaccine, drug resistance of parasites, insecticide 
resistance of mosquito vectors and changing socio-economic and environmental factors [26]. 
As measures to prevent infection are not fully efficient, early diagnosis and drug treatment 
form the fundaments of malaria control strategies. Several types of drugs are available for 
malaria treatment, most of which are solely directed against the asexual parasite stages that 
cause disease symptoms. Some antimalarial drugs, such as artemisinin derivatives, also 
affect the sexual transmission stages [27, 28], while in contrast chloroquine and 
sulphadoxine-pyrimethamine (SP) induce development of gametocytes [29-32]. Such drug-
induced effects on gametocytes may affect transmission and therefore also the spread of 
drug resistance. Evaluation of drug treatment policies is needed [33] to optimise the use of 
available drugs, to decrease the spread and development of drug resistance and to reduce 
the risk of compulsory switching to drugs that are still effective but more expensive. 
 
Accurate quantification of transmission stages is of great importance to monitor the spread 
of malaria over a population, including the spread of drug resistance. Furthermore, 
quantification of gametocytes is valuable for epidemiological studies and studies that 
evaluate control measures, especially those aimed at reducing the transmission of malaria. 
Currently, such studies mostly rely on microscopical detection of gametocytes. Microscopic 
analysis is routinely used for diagnosis of malaria but with its detection limit of 1-20 parasites 
and about 16 gametocytes per microlitre of blood is not always sensitive enough and too 
laborious for the purpose of these studies. Therefore, sexual stages are rarely included in 
drug resistance monitoring or in evaluation of interventions targeting transmission. As 
transmission is an essential part of the P. falciparum life cycle, with potential targets for 
control, it is of major importance to provide quantitative, sensitive tools to adequately study 
this part of the life cycle. 
 
MOLECULAR DETECTION OF PLASMODIUM FALCIPARUM 
Newly developed molecular techniques for P. falciparum detection based on DNA or RNA 
amplification are more sensitive than microscopy but also have their limitations and 
encounter problems with either quantification or stage-specific detection and are therefore 
not applied routinely. Polymerase Chain Reaction (PCR) can detect parasite DNA with a 
detection limit of up to 20 parasites/ml of blood [34-37] but is semi-quantitative and cannot 
accurately quantify the number of parasites present. Quantitative real-time PCR (Real-time 
Q-PCR) was developed for detection of Plasmodium falciparum 18S small subunit ribosomal 
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RNA genes and can detect 20 parasites/ml of blood [38]. This technique however, requires 
relatively large quantities of venous blood (0.5 ml) and leukocytes need to be filtered from 
the blood samples to prevent processing problems, caused by otherwise gelatinous DNA 
preparations [38]. Additionally, PCR techniques based on amplification of DNA cannot detect 
various developmental stages of the parasites, including gametocytes. Reverse-
transcriptase PCR (RT-PCR) avoids this problem and can detect various developmental 
stages in a quantitative and sensitive assay based on stage-specific gene expression [39]. 
However, since most Plasmodium genes have no introns (i.e. the DNA is identical to the 
RNA sequence), this method cannot unambiguously detect RNA without complete removal 
of genomic DNA from the sample. As DNAse treatment of the isolated RNA frequently does 
not provide absolute removal of genomic DNA, this affects accurate quantification using RT-
PCR. Alternative techniques are needed for sensitive and accurate quantification of both 
total parasite load and gametocytes in large numbers of samples. One technique that may 
avoid the above-described problems is quantitative nucleic acid sequence-based 
amplification (QT-NASBA).  
 
QUANTITATIVE NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION 
QT-NASBA utilises the activities of three enzymes (AMV-RT, RNase H and T7 RNA 
polymerase) and two target-specific primers, of which one includes a T7 polymerase-
promoter, for continuous and direct amplification of RNA molecules in a single mixture at a 
temperature of 41°C [40, 41] (figure 1.3). The low temperature ensures that primers only 
anneal to single stranded target RNA and prevents amplification of genomic DNA that may 
be present in the sample.This allows for specific detection of living, metabolically active cells 
and organisms. The amplification process is part of a system, which includes a nucleic acid 
isolation procedure, and powerful detection methodology. QT-NASBA can detect various 
developmental stages of the same organism through measurement of stage-specific gene-
expression and can be performed on small (50 µl) finger prick blood samples. The high 
accuracy, sensitivity and quick reaction times that allow for high throughput of samples, 
make QT-NASBA extremely suitable for large-scale epidemiological investigations. NASBA 
has been successfully used for the detection and quantification of several disease agents 
such as HIV-1 [42], Hepatitis A [43], B [44] and C viruses [45, 46]. The ability of NASBA to 
detect treatment efficacy has been shown for e.g. Mycobacteria [47, 48] and HIV-1 [49, 50]. 
Frequently, NASBA proved to be more sensitive and specific than other available molecular 
techniques, particularly for RNA targets [51].  
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QT-NASBA for detection of Plasmodium falciparum parasite loads has a detection limit of 10 
parasites/ml of blood [52, 53]. This technique is based on specific amplification of 18S rRNA 
of the parasites and detection using electrochemiluminescence (ECL). Due to the possibility 
of QT-NASBA to accurately quantify RNA in a DNA background, it can be applied to detect 
various parasite developmental stages using their stage-specific differences in gene 
expression. For Plasmodium falciparum this may enable separate quantification of 
gametocytes in the blood sample. 
 
 
 
 
 
Figure 1.3. Principle of nucleic acid sequence-based amplification. Primer 1, including a T7 promoter site, 
hybridises to the single-stranded target RNA (but not to DNA) and is extended by AMV-RT using free nucleotides 
from the reaction mixture. The produced cDNA:RNA hybrid is hydrolysed by RNAse H that destroys the original 
target RNA. Primer 2 anneals to the remaining single stranded DNA copy, is extended by AMV-RT and results in 
a double stranded DNA sequence with a double stranded, and thus functional, T7 promoter site. New RNA is 
transcribed from this sequence using T7 RNA polymerase. Each new RNA molecule re-enters the reaction until 
the primers are finished. From the time of primer depletion, amplification will depend on transcription only, 
resulting in a linear increase of amplicons.  
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AIM AND OUTLINE OF THE THESIS 
The primary objective was to study the prevalence and dynamics of P. falciparum sexual 
stages in the field. More detailed knowledge on this subject may benefit malaria control that 
aims to reduce transmission of malaria. 
A more sensitive tool for the detection of P. falciparum gametocytes, compared to standard 
microscopic detection, was required. Therefore, a molecular technique based on RNA 
amplification (QT-NASBA) was developed for quantification of P. falciparum parasites, 
sexually committed parasites and mature gametocytes [chapter 2]. Subsequently, these QT-
NASBAs were improved with real-time detection using molecular beacon technology and 
compared to other techniques used for parasite quantification [chapters 3 and 5]. To 
facilitate the collection of samples for QT-NASBA during field studies, the protocol for 
storage of samples at -70ºC was adapted for storage at -20ºC [chapter 4].  
The quantitative NASBAs were then used to study (sub)microscopic asexual and sexual 
stage parasite dynamics in adult volunteers that were experimentally infected with P. 
falciparum [chapter 2], in Kenyan children after drug treatment for uncomplicated 
symptomatic P. falciparum infection [chapter 5] and in individuals of all ages with 
asymptomatic P. falciparum in Burkina Faso [chapter 6]. 
The potential of submicroscopic gametocytaemia to be transmitted from the human host to 
the mosquito vector was determined with mosquito infections in the laboratory and confirmed 
with transmission studies in the field [chapter 7]. The infectivity of (sub)microscopic 
gametocytes to Anopheles gambiae was studied in the field in Kenyan children after 
antimalarial drug treatment [chapter 8]. The results presented in this thesis are summarised 
and discussed in chapter 9. 
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ABSTRACT 
Two quantitative nucleic acid sequence-based amplification assays (QT-NASBA) based on 
Pfs16 and Pfs25, have been developed to quantify sexual stage commitment and mature 
gametocytes of Plasmodium falciparum. Pfs16 mRNA is expressed in all sexual forms 
including sexually committed ring stages while expression of Pfs25 mRNA is restricted to 
late stage gametocytes. Both assays showed a sensitivity of one sexual stage parasite/µl of 
blood. 
Blood samples from experimentally infected non-immune human volunteers were tested for 
Plasmodium falciparum by standard microscopy, a previously developed asexual 18S rRNA 
QT-NASBA, Pfs16 and Pfs25 mRNA QT-NASBA. Pfs16 QT-NASBA was positive in 9 out of 
10 volunteers within 48 hours after first detection of 18S rRNA, mostly before or at the day of 
positive microscopy. In contrast, the Pfs25 mRNA QT-NASBA was negative during the 28 
days of follow-up, but consistently positive in gametocyte samples from naturally infected 
Kenyan patients. These data suggest that sexual stage commitment can occur early in the 
blood-stage infection without successful maturation into infectious gametocytes. 
In conclusion, Pfs16 and Pfs25 QT-NASBA assays in combination with a previously 
developed asexual stage QT-NASBA allow for the separate quantification of all 
developmental stages present in the circulation. The application of sexual stage QT-NASBA 
assays may contribute to a better understanding of the biology and epidemiology of malaria 
transmission. 
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INTRODUCTION 
Malaria is caused by Plasmodium parasites, of which the asexual stages are responsible for 
the clinical symptoms while sexual stages (gametocytes) are necessary for transmission of 
the parasite from man to mosquito. The presence and infectiousness of gametocytes in the 
circulation determine the success of transmission from humans to mosquitoes, but the 
process of gametocytogenesis and maturation has not been elucidated. Gametocytes are 
derived from only a small fraction of asexual parasites and only a proportion of patients with 
a primary infection develop patent gametocytaemia [6]. Molecular analyses have shown that 
commitment to the sexual pathway takes place in the asexual generation preceding 
gametocyte development, before the merozoite invades a new red blood cell [19, 21, 22, 54]. 
Sexually committed merozoites and ring forms cannot be distinguished from asexual 
parasites by morphology [19, 55] but stage-specific metabolic processes do occur. It is 
unknown whether asexual parasites of gametocyte-free infections (i) do not commit to sexual 
differentiation or (ii) do commit, but fail to complete development into mature gametocytes. 
To understand the epidemiology and biology of malaria and for the development of control 
strategies, it is important to study factors that govern induction, maturation, infectiousness 
and dynamics of gametocytes in vivo. 
As a result of sequestration in the vasculature, only asexual ring stages, sexually committed 
ring stages and mature gametocytes of P. falciparum are present in the circulation. 
Differential expression of the sexual stage-specific genes Pfs16 and Pfs25 allows separate 
quantification of these stages (figure 2.1). Although Pfs16 protein synthesis is gametocyte-
specific [17, 55-58], Pfs16 promoter activity can be detected in ring stages and mRNA is 
observed within 24 hours of red blood cell invasion [56, 59, 60]. This transcriptional activity is 
considered a marker for sexually committed ring stages [19, 56] and is the earliest marker 
available to detect gametocytogenesis. The expression of Pfs16 mRNA identifies circulating 
sexual stage parasites, comprising sexually committed ring stages and fully mature 
gametocytes. Of all parasite stages in the circulation, Pfs25 mRNA is expressed only in 
stage V gametocytes, which enables its use as a marker to separately quantify mature 
gametocytes [39]. 
Quantitative nucleic acid sequence-based amplification (QT-NASBA) has been developed 
for specific quantification of single-stranded RNA in the presence of DNA, regardless of the 
presence of introns in the target sequence [40]. QT-NASBA has been successfully applied 
for highly sensitive quantification of P. falciparum by detection of type A-18S rRNA, that is 
expressed by all developmental stages of the parasite [52]. 
In this paper we present the development of the Pfs25 and Pfs16 mRNA QT-NASBA for 
separate quantification of P. falciparum developmental stages present in the circulation. 
Chapter 2 
 18 
These assays were used to study early sexual stage development in naïve human 
volunteers experimentally infected with P. falciparum malaria. 
 
  Pfs16 mRNA  - neg 
Pfs25 mRNA  - neg 
18S rRNA  - pos 
Pfs16 mRNA  - pos 
Pfs25 mRNA  - neg 
18S rRNA  - pos 
Pfs16 mRNA  - pos 
Pfs25 mRNA  - pos 
18S rRNA  - pos 
asexual stage 
sexually committed 
mature gametocytes 
 
 
 
MATERIALS AND METHODS 
Sample collection 
Samples were collected from continuous or synchronised in vitro parasite cultures of P. 
falciparum isolate NF54 [9]. Samples from in vivo infections were collected from ten 
volunteers experimentally infected with P. falciparum NF54 [38]. Briefly, the volunteers were 
infected by 5 mosquitoes, resulting in a 100% infection rate, and treated with chloroquine 2 
days (volunteers 1-5) or directly (volunteers 6-10) after parasites could be detected by 
microscopical investigation of a thick blood smear. Blood samples were taken twice a day 
from day 4 post-infection until parasites were detected by microscopical examination of the 
blood, subsequently daily until cured by treatment. Thick blood films were prepared of all 
samples to microscopically count parasites. Total follow-up period was 28 days. The study 
was approved by the ethical committee of the Radboud University Nijmegen Medical Centre 
(CWOM 0011-0262, 2002/170). 
 
Nucleic acid extraction 
Blood samples (100 µl) were mixed with 900 µl of guanidium isothiocyanate lysis buffer [61] 
and 107, 5x104 and 5x102 molecules of respectively 18S, Pfs16 and Pfs25 internal 
quantification control (in vitro quantitative RNA or Q-RNA) before RNA isolation as described 
by Boom et al. [61].  
Figure 2.1. Differential expression of the sexual stage-specific genes Pfs16 and Pfs25 allows separate
quantification of all developmental stages of the parasites that are present in the circulation. Neg: negative, no RNA
expression; pos: positive, RNA expression.  
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QT-NASBA 
Nucleic acid sequence-based amplification was performed using NucliSens Basic Kit for 
amplification according to the manufacturer’s manual (bioMérieux) at a KCl concentration of 
40mM for Pfs16 and 80mM for 18S and Pfs25 QT-NASBA. The reaction mixture including 
reverse and forward primers was incubated with the RNA extract at 65°C for 5 minutes and 
subsequently at 41°C for 5 minutes. Five µl of Nuclisens enzyme mixture (AMV-RT, RNase 
H and T7 RNA polymerase) was added and amplification allowed for 90 minutes at 41°C. 
 
Quantification of amplicons by electrochemiluminescence (ECL) 
Amplification products were hybridised for 30 minutes at 41°C to 10 µl ruthenium-labelled 
generic probe (bioMérieux, NucliSens Basic Kit detection) and 10 µl of capture probe bound 
to streptavidin-coated magnetic beads. The emitted light is detected by a photoelectric cell, 
thus offering a precise measurement of amplicons [62]. For quantification, wild type mRNA 
was co-amplified with a fixed amount of in vitro Q-RNA, which is identical to the wild type 
(WT) sequence apart from a 20-basepair rearrangement in the centre. WT and Q-RNA are 
competitively amplified with the same primers in a single tube NASBA reaction. WT and Q 
amplicons are separately detected with respectively WT and Q-capture probes and the ratio 
of their signals can be used for precise quantification of the WT copy numbers originally 
present in the sample. 
 
Calculations 
Both WT and Q-RNA are competitively amplified by the same primer set. This enables 
accurate quantification, related to the fixed number of Q-RNA molecules present in the 
reaction. The ECL provides a WT and a Q-signal for each sample and the ratio between 
these signals is directly related to the number of WT mRNA molecules present in the 
sample. In each experiment, a standard curve of blood samples spiked with 108, 106, 104, 
103 and 0 ring stage parasites or gametocytes/ml of blood mixed with the appropriate Q-
RNAs (107, 5x104 and 5x102 molecules of 18S, Pfs16 and Pfs25 Q-RNA, respectively) was 
included. ECL results were calculated as described in Schoone et al. [52]. To prevent 
problems caused by an input of zero parasites in the standard curves, all log input number of 
parasites were transformed using log (number of parasites + half the detection unit) 
according to van Lieshout et al. [63], which corresponds to 0.005 parasites per ml of blood.  
Quantification of absolute numbers of sexually committed ring stages by Pfs16 QT-NASBA 
was only possible in the in vitro studies where synchronised, asexual-free young 
gametocytes (stage I-II) were included in the analyses. Pfs16 mRNA levels in ring stages 
were quantified relative to the mRNA levels present in synchronised young gametocytes 
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(stage I-II). Results from the experimental infections are presented as Pfs16 ECL signals 
corrected for the background signal at day 0, which should have a linear relationship to the 
absolute number of sexually committed ring stages. 
 
Primer and probe sequences 
18S NASBA primer and probe sequences are described in [52]. Primers and probes for 
specific amplification and detection of P. falciparum Pfs16 (GenBank Accession no. M64705) 
and Pfs25 mRNA (GenBank Accession no. X07802) in QT-NASBA were designed and 
showed no homologies (FASTA) with human and invertebrate sequences. 
 
Generic sequence (genseq)  5’-GATGCAAGGTCGCATATGAG-3’ 
T7 promoter sequence (T7)  5’-AATTCTAATACGACTCACTATAGGGAGAAGG-3’ 
Reverse primer Pfs16.1.2  5’-T7-AGCTAGCTGAGTTTCTAAAGGCA-3’  
Forward primer Pfs16.2.2  5’-genseq-AGTTCTTCAGGTGCCTCTCTTCA-3’ 
Reverse primer Pfs25-P1  5’-T7-CATTTACCGTTACCACAAGTTA-3’ 
Forward primer Pfs25-P2  5’-genseq-GACTGTAAATAAACCATGTGGAGA-3’  
Capture probe Pfs16 WT  5’-biotin-GCTGTTGGACCTAATCTAGGTGGA-3’. 
Capture probe Pfs16 Q  5’-biotin-GCAAATACAGTCCCAATCCTGGCT-3’ 
Capture probe Pfs25 WT  5’-biotin-CCCGTTTCATACGCTTGTAA-3’. 
Capture probe Pfs25 Q  5’-biotin-CTGTTTACCACTAGCTCTGA-3’. 
 
In vitro RNA 
Pfs16 WT in vitro RNA: Primers 292 and 399 (Dr. I. Moelans) were modified to include 
restriction sites, resulting in primer 292A (5’-6G-EcoRI-CAACATGAATATTCGAAAGTT 
CATACC-3’) and 399A (5’-6G-HindIII-AGAATCATCTCCTTCGTCTTCTTC-3’). These 
primers were used to amplify a 481bp region of the Pfs16 gene. The amplified fragment was 
cloned into plasmid pGEM-3Z and transfected to JM109 cells. After overnight culture 
plasmids were purified from the cells, DNA extracted and, after linearisation, large quantities 
of in vitro Pfs16 WT-RNA were transcribed using T7 RNA transcription. In vitro RNA was 
quantified by measurement of OD260nm. 
Pfs16 Q in vitro RNA: Pfs16 Q-RNA was designed using random rearrangements of 
nucleotides in the 24bp region where the Pfs16 WT-RNA probe hybridises. The resulting 
Pfs16 Q-sequence showed no homology with human and invertebrate nucleic acids. The 
Pfs16 Q-construct including primer sites was ordered directly from Isogen, amplified by 
primers Pfs16.1.2 and Pfs16.2.1 (5’-GATGCAAGGTCGCATATGAGCGCTGGAAAAGGA 
TCCCCTTCA-3’) and cloned directly into pGEM-T Easy plasmid. In vitro Pfs16 Q-RNA was 
obtained as described for Pfs16 in vitro WT-RNA. Q-RNA can be amplified by primers 
Pfs16.1.2 and Pfs16.2.2.  
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Pfs25 WT in vitro RNA: Primers Pfs25-P1-HindIII: 5’-6G-AAGCTT-CATTTACCGTTACC 
ACAAGTTA-3' and Pfs25-P2-EcoRI: 5’-6G-GAATTC-GACTGTAAATAAACCATGTGG AGA-
3’ were used to amplify a 156bp region of the Pfs25 gene. The amplified fragment was 
cloned into plasmid pGEM-T Easy and in vitro Pfs25 WT-RNA was obtained as described for 
Pfs16 in vitro WT-RNA. 
 
Pfs25 Q in vitro RNA: Pfs25 Q-RNA was designed using random rearrangements of 
nucleotides in the 20-nucleotide region where the Pfs25 WT capture probe hybridises. The 
resulting Q-sequence showed no homology with human and invertebrate nucleic acids. The 
Pfs25 Q-construct including primer sites was ordered directly from Isogen, amplified by 
primers Pfs25-P1-HindIII and Pfs25-P2-EcoRI and cloned directly into pGEM-T Easy 
plasmid. In vitro Pfs25 Q-RNA was obtained as described for the Pfs16 in vitro WT-RNA. 
Pfs25 Q-RNA can be amplified by primers Pfs25-P1 and Pfs25-P2.  
 
RESULTS 
Detection limit and stage-specificity 
The sensitivity of NASBA assays depends on the efficiency of amplification and the sample 
volume used for both RNA extraction and NASBA. To test the sensitivity of the QT-NASBA 
procedure for Pfs25 and Pfs16 mRNA detection, 10-fold dilution series of in vitro wild type 
RNA were analysed. The lower detection limit for reliable quantification was 103 to 104 copies 
per reaction for both Pfs16 and Pfs25 in vitro WT-RNA (data not shown), which should be 
sufficiently sensitive to detect very low numbers of sexual stage parasites in blood samples.  
Figure 2.2 shows that for gametocytes, the lower detection limit for reliable quantification 
was at least 103 gametocytes/ml of blood for both Pfs16 and Pfs25. The relation between the 
log of the microscopically counted number of gametocytes in the sample and the 
quantification result by QT-NASBA was highly significant (p<0.005) for both Pfs16 and Pfs25 
QT-NASBA, with an r2 of 0.965 and 0.979, respectively.  
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Gametocyte quantification
of mature gametocytes (purified stage
IV-V) from in vitro culture by QT-
NASBA. Gametocyte samples were
diluted with non-infected blood, RNA
extracted and QT-NASBA performed
for 18S rRNA, Pfs16 mRNA and Pfs25
mRNA. The three assays were each
repeated at least 7 times on
independent gametocyte samples,
error bars indicate standard errors. 
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Pfs16 QT-NASBA analyses showed that parasite samples from continuous in vitro culture of 
NF54 P. falciparum were consistently positive for Pfs16 mRNA. This was also the case in 
preparations from synchronised ring stage samples. In a purified ring stage sample 
containing 108 ring stage parasites, 1% of parasites were positive for Pfs16 mRNA and 1 in 
105 parasites (0.001%) for Pfs25 mRNA.  These analyses showed that purity of those 
samples with respect to stage III-V gametocytes was  >99.99 %. 
 
Experimental human infections 
To study early sexual stage development of P. falciparum parasites in vivo, blood samples 
collected during experimental infections were analysed by 18S rRNA QT-NASBA, Pfs16 and 
Pfs25 mRNA QT-NASBA. The 18S rRNA QT-NASBA first detected parasites at day 6.3 - 7.0 
post-infection (table 2.1). Detection of asexual P. falciparum parasites by 18S rRNA QT-
NASBA was on average 1.4 days (range 0.3 – 2.3) earlier compared to standard 
microscopy. Pfs16 mRNA QT-NASBA was positive in 9 out of 10 volunteers within 48 hours 
after first detection of 18S rRNA. In 8 out of 10 volunteers Pfs16 mRNA was measurable 
before or at the time of microscopical detection of asexual parasites. Pfs25 mRNA was not 
found in any of the blood samples of the volunteers during the 28-day follow-up period. 
 
 
 
Day of first positive sample after infection 
Volunteer  18S rRNA Pfs16 mRNA Microscopy 
1  7.0  8.0  9.0 
2  7.0  7.3  8.0 
3  6.3  7.3  8.0 
4  6.3  7.0  7.0 
5  7.0  9.0  8.0 
6  7.0  7.3  9.3 
7  6.3  7.3  8.3 
8  7.0  8.0  9.3 
9  7.0  negative  7.3 
10  7.0  7.3  7.3 
 
The pattern of parasite development (representative examples in figure 2.3) was similar in all 
10 volunteers, with a mean maximum parasitaemia of 106 and 6.3x104 parasites/ml of blood 
for the groups that received chloroquine treatment at respectively 2 days (volunteers 1-5) 
and directly after (volunteers 6-10) microscopical detection of parasites. Pfs16 mRNA could 
only be detected during a short time period within a proliferation cycle and was found during 
most but not all parasite proliferation cycles. A direct quantitative relation between the levels 
of Pfs16 mRNA and 18S rRNA could therefore not be identified.  
 
 
Table 2.1. Detection of parasitaemia by different QT-NASBAs and
by microscopy in experimental human P. falciparum infections.
Pfs25 mRNA QT-NASBA was negative in all samples. 
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Figure 2.3. Representative results of 18S rRNA (triangles) and Pfs16 mRNA (squares) QT-NASBA for volunteers 
1 and 5 in the experimental infections. Time of chloroquine treatment is indicated in the graph by the dashed line. 
The number of parasites is calculated by 18S rRNA QT-NASBA, with the lower detection limit for reliable 
quantification set to 100 parasites/ml of blood. The results of Pfs16 mRNA QT-NASBA are presented as the 
signal resulting from QT-NASBA (corrected for the background at day 0), which should have a linear relation to 
the absolute numbers of sexually committed parasites. 
 
DISCUSSION 
Two QT-NASBAs have been developed for molecular detection of sexual stages of P. 
falciparum: The Pfs16 QT-NASBA for identification of the earliest sexual stages and the 
Pfs25 QT-NASBA for mature gametocytes. These assays with a sensitivity of at least 1 
parasite/µl can be used both for test samples from in vitro cultures as well as blood samples. 
There is a great need for more sensitive and user-friendly methods for sexual stage 
detection in epidemiological studies on malaria transmission.  
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The usually low prevalences and densities of gametocytes in infected persons hamper 
studies using standard microscopy. Microscopical investigation of a thick blood smear has a 
detection limit of 16 gametocytes/µl when counting against the standard 500 white blood 
cells. To obtain sensitivity of 1 parasite/µl, over 1000 thick blood smear fields would have to 
be examined. It has been shown that transmission of Plasmodium parasites by direct 
feeding of mosquitoes occurred in blood samples that were apparently gametocyte negative 
by microscopy [64]. 
Gametocyte detection by reverse transcriptase PCR (RT-PCR) has been developed as an 
alternative [20, 39, 65, 66], but this method cannot quantify gametocytes and requires 
nested PCR reactions to obtain high sensitivity of up to one gametocyte/µl of blood. 
Additionally, the application of RT-PCR for Plasmodium is complicated by the fact that many 
genes in Plasmodium do not contain introns, resulting in identical sequences for both RNA 
and DNA. RT-PCR is therefore highly dependent on efficient removal of genomic DNA and 
generally requires complicated protocols for RNA extraction and additional PCR to test for 
contaminating genomic DNA in each sample. 
The sensitivity of Pfs25 QT-NASBA is similar to that of the RT-PCR developed by Babiker et 
al. [39]. The sexual-stage specificity of the Pfs25 QT-NASBA was addressed by using 
synchronised ring stage preparations of in vitro cultures. Positive reactions were found but 
these samples could have been contaminated with stage III-V gametocytes below the 
microscopical detection limit; 1 gametocyte per 10,000 ring stage parasites (>99.99% purity) 
is sufficient for detection by the Pfs25 QT-NASBA. Convincing evidence for the sexual stage 
specificity of the Pfs25 QT-NASBA was obtained from blood samples from the experimental 
human malaria infections, which were all negative. As the first detection of parasites is at 
day 6.3-7 after infection (this paper) and the duration of gametocyte development in vitro is 7 
days [9], the samples of the first 13-14 days after infection were guaranteed gametocyte-
free. However, asexual parasite loads were sufficiently high to detect Pfs25 signals in case 
the assay was not sexual stage-specific. Control samples from naturally infected Kenyan 
gametocyte carriers were consistently positive (data not shown). 
High levels of Pfs16 mRNA were found in synchronised ring stage samples from in vitro 
culture, which could not account for low-level contaminations with stage III-V gametocytes 
even when considering the presence of younger gametocytes (stage I-II). Therefore the high 
Pfs16 mRNA levels must be expressed by sexually committed, but morphologically asexual 
ring stage parasites. This is supported by the presence of Pfs16 mRNA in the earliest 
phases of the human experimental malaria infections i.e. within 48 hours after the first 
detection of 18S P. falciparum rRNA. Although no quantitative relation was found between 
the number of asexual parasites and the Pfs16 mRNA QT-NASBA signal, Pfs16 mRNA 
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levels tend to follow the pattern of asexual stage development. The lack of a direct 
quantitative relation between the level of Pfs16 mRNA and asexual parasitaemia may partly 
be the result of mRNA levels below the detection limit of Pfs16 QT-NASBA. Additionally, the 
rapid disappearance Pfs16 mRNA from the circulation within one proliferation cycle indicates 
that a variable amount of sexually committed parasites is present in the circulation and 
suggests some influence of sequestration of sexually committed parasites. The 18S rRNA 
QT-NASBA, previously developed by Schoone et al. [52], was used for sensitive detection of 
P. falciparum parasites in blood samples. Sexual commitment was shown to occur early 
during a primary infection, probably already in the parasite stages released from the liver. 
Pfs16 mRNA has shown to be a useful marker for the onset of sexual stage development, 
but by itself is not a suitable quantitative marker to predict subsequent development and 
maturation of gametocytes and should therefore be combined with Pfs25 mRNA QT-NASBA.  
In conclusion, this study shows that QT-NASBA is a valuable tool to quantify different 
developmental stages of Plasmodium falciparum. It can be used for the evaluation of control 
measures and epidemiological studies that require sensitive and specific quantification of P. 
falciparum parasites and gametocytes with more detailed quantitative information of 
Plasmodium falciparum sexual stage development. 
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ABSTRACT 
Determination of the number of malaria parasites by routine or even expert microscopy is not 
always sufficiently sensitive for detailed quantitative studies on the population dynamics of 
Plasmodium falciparum, such as intervention or vaccine trials. To circumvent this problem, 
two more sensitive assays, real-time quantitative nucleic acid sequence-based amplification 
(QT-NASBA) and real-time quantitative PCR (QT-PCR) were compared for quantification of 
P. falciparum parasites. QT-NASBA was adapted to molecular beacon real-time detection 
technology, which enables a reduction of the time of analysis and of contamination risk, 
while retaining the specificity and sensitivity of the original assay. Both QT-NASBA and QT-
PCR have a sensitivity of 20 parasites/ml of blood, but QT-PCR requires a complicated DNA 
extraction procedure and the use of 500 µl venous blood to achieve this sensitivity, 
compared to 50 µl of finger prick blood for real-time QT-NASBA. Both techniques show a 
significant correlation to microscopic parasite counts, and the quantification results of the two 
real-time assays are significantly correlated for in vitro as well as in vivo samples. However, 
in comparison to real-time QT-PCR, results of real-time QT-NASBA can be obtained 12 
hours earlier, with relatively easy RNA extraction and use of finger prick blood samples. The 
prospective development of multiplex QT-NASBA for detection of various P. falciparum 
developmental stages increases the value of QT-NASBA for malaria studies. Therefore, for 
studies requiring sensitive and accurate detection of P. falciparum parasites in large 
numbers of samples, the use of real-time QT-NASBA is preferred over that of real-time QT-
PCR.  
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INTRODUCTION 
Routine clinical diagnosis of malaria is usually based on microscopic detection of 
Plasmodium parasites in blood smears. However, this technique is relatively laborious when 
large numbers of samples need to be quantified simultaneously. Furthermore, the detection 
limit of microscopy, 1-20 parasites per µl of blood, may not always be sufficiently sensitive. 
Parasite densities below the detection level of microscopy may play an important role in 
Plasmodium population dynamics and the epidemiology of the disease. Therefore, the 
availability and use of more sensitive detection techniques is a prerequisite for many 
research projects. With the rapid developments in the field of molecular biology, several 
nucleic acid-based amplification methods, including PCR, reverse transcriptase PCR and 
nucleic acid sequence-based amplification (NASBA) [34, 38, 52, 53, 67, 68] are now 
available for detection of Plasmodium parasites. Because many studies require accurate and 
sensitive quantification of parasites, most of these techniques have been adapted for 
quantitative analysis [38, 52, 68-70]. In preparation of vaccine trials and epidemiological 
studies directed at evaluation of intervention, the present study was designed to evaluate the 
newly developed real-time quantitative NASBA (QT-NASBA) and to compare the assay to 
another quantitative nucleic acid-based method used for quantification of P. falciparum 
parasites, real-time quantitative PCR (QT-PCR).  
Schoone et al. [52] developed a QT-NASBA based on the detection of P. falciparum 18S 
rRNA with a sensitivity of 10 to 50 parasites/ml [52]. This method can be applied to 50 µl 
finger prick blood samples and has complete specificity for P. falciparum. This QT-NASBA 
assay is a combination of RNA extraction, amplification of the RNA target plus an internal 
control, and end point detection of amplification products by electrochemiluminescence 
(ECL). Competitive co-amplification of an internal control enables accurate quantification [52, 
71]. In the present study, the QT-NASBA was adapted to real-time molecular beacon 
technology [72] to avoid inaccurate quantification at high parasite densities, which may occur 
with endpoint detection due to depletion of reagents during the amplification reaction. 
Moreover, the closed-tube format of the assay highly reduces the risk of contamination and 
thus of false-positive results. The real-time QT-NASBA allows accurate quantification of as 
many as 48 samples in 4 hours, including RNA extraction. 
The adaptation of the QT-NASBA to real-time quantification of P. falciparum parasites now 
allows direct comparison to real-time P. falciparum QT-PCR [38], which is based on 
detection of DNA encoding for 18S rRNA. This real-time QT-PCR has a sensitivity of 20 
parasites/ml of blood when 500 µl blood samples are used, with accurate quantification of 48 
samples within 16 hours. 
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MATERIALS AND METHODS  
Real-time QT-NASBA 
Real-time P. falciparum QT-NASBA for 18S rRNA (Genbank accession number M19172.1) 
was performed on a NucliSens EasyQ analyser (bioMérieux) using the NucliSens BasicKit 
for amplification according to manufacturer’s manual at a KCl concentration of 80mM. 
Reactions were carried out in a total volume of 10 µl per reaction. The forward primer was 
5’-gtcatctttcgaggtgactt-3’ (nucleotides 1136 to 1155); the reverse primer was 5’-
aattctaatacga ctcactatagggagaaggaactttctcgcttgcgcgaa-3’ (T7 promoter sequence, linker 
and nucleotides 1216 to 1235); the Pf18S molecular beacon was 5’-6-carboxyfluorescein-
cgatcg-gagaaatcaaa gtctttggg-cgatcg-dimethylaminoazosulfonic acid-3’ (molecular beacon 
stem of 6 paired nucleotides and nucleotides 1182 to 1201). Time to positivity, i.e. the time 
point during amplification at which the number of target amplicons detected became higher 
than the mean for three negative controls plus 20 standard deviations, was calculated. The 
use of a standard ring stage parasite dilution series allows exact calculation of the number of 
parasites present in unknown samples. 
 
Real-time QT-PCR 
Real-time QT-PCR analysis and subsequent calculations were performed on an ABI PRISM 
7700 sequence detection system (Applied Biosystems) using a fluorescently labelled 
TaqMan probe to enable continuous monitoring of amplicon formation. The procedures, 
primer and probe sequences are those presented by Hermsen et al. [38], except that the 
probe is now labelled with tetrachloro-6-carboxy-fluorescein (TET). A minimum of 0.5 ml of 
whole blood is needed to obtain a sensitivity of 20 parasites/ml of blood, and the blood 
needs to be filtered through a Plasmodipur filter to remove white blood cells that may cause 
viscosity problems during DNA extraction. The number of parasites is calculated from the 
threshold cycle, i.e. the amplification cycle number at which emitted fluorescence exceeds 
the baseline emission plus 10 standard deviations. 
 
In vitro samples 
The detection limit and accuracy of quantification by real-time QT-NASBA were evaluated 
using purified ring stage parasites and purified stage IV to V gametocytes from in vitro 
culture of P. falciparum isolate NF54 [9].  Purified parasites were diluted in whole blood to 
obtain 10-fold dilution series, ranging from 10 to 106 ring stage parasites (n=3 for each 
concentration) and 102 to 107 gametocytes (n=4 for each concentration) per ml of blood as 
counted by microscopy. RNA was independently extracted for each dilution series, and 
quantification by real-time QT-NASBA was performed three times for each ring stage sample 
and four times for each gametocyte sample. For comparison with real-time QT-NASBA, the 
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dilution series of 10 to 106 ring stage P. falciparum NF54 parasites per ml of blood were also 
used for DNA extraction and parasite quantification by real-time QT-PCR. Quantification by 
real-time QT-PCR was performed three times in duplicate. 
 
In vivo samples 
For direct comparison of samples from in vivo infections, 13 samples from an individual 
participating in a human experimental P. falciparum infection study were analysed in 
duplicate both by real-time QT-NASBA and by real-time QT-PCR. The human experimental 
infection study, performed in preparation for vaccine trials, was approved by the ethics 
committee of the Radboud University Nijmegen Medical Centre (CWOM 0011-0262, 
2002/170) and a detailed description of the study is given by Hermsen et al. [38]. Real-time 
QT-PCR was used for early detection of parasites (2-4 days before microscopical detection 
of parasites and treatment [38]) in the volunteers and real-time QT-NASBA was included for 
comparison, with the aim of evaluating QT-NASBA for future studies. Parasite quantification 
of in vivo samples by the two different assays was compared using Spearman’s correlation 
test. 
 
RESULTS 
In vitro samples 
Results of quantification of P. falciparum parasites by real-time QT-NASBA and real-time 
QT-PCR were compared with microscopic parasite counts. Highly significant correlations 
were found for quantification of ring stage parasites and gametocytes by NASBA (figure 
3.1A) (for ring stages, R2=0.942 and p<0.01; for gametocytes, R2=0.966 and p<0.01) and for 
quantification of ring stage parasites by PCR (figure 3.1B) (R2=0.985; p<0.01).  
The interassay variation of both assays was calculated as standard deviation/average x 
100% (table 3.1). The interassay variation includes variation of both amplification and nucleic 
acid extraction, because all samples were processed individually. For real-time QT-NASBA, 
the interassay variation tends to be low and relatively stable over the range of parasite 
concentrations tested, although the interassay variation seems to increase at the lowest 
tested parasite concentrations of 10 asexual parasites per ml of blood. The interassay 
variation of real-time QT-PCR is similar to that of real-time QT-NASBA but could not be 
calculated accurately for the lower concentrations due to negative results in the real-time 
QT-PCR (table 3.1). The detection limit for both real-time QT-NASBA and real-time QT-PCR 
is 20 parasites/ml of blood.  
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Figure 3.1. (A) Mean number of P. falciparum ring stage parasites () and gametocytes (circles) in 10-fold dilution 
series quantified by real-time 18S rRNA QT-NASBA. Error bars indicate standard deviations. The log number of 
parasites per sample as counted by microscopy shows a highly significant correlation with the time to positivity 
(TTP) as calculated by real-time QT-NASBA (for ring stage parasites, R2=0.942 and p<0.01; for gametocytes, 
R2=0.966 and p<0.01). (B) Mean number of P. falciparum ring stage parasites in 10-fold dilution series quantified 
by 18S real-time QT-PCR. The mean is calculated for 7 observations with 10 parasites/ml, 12 observations with 
102 parasites/ml and 18 observations with 103 to 106 parasites/ml. Error bars indicate standard deviations. The 
log number of parasites per sample as counted by microscopy shows a highly significant correlation with the 
threshold cycle as calculated by real-time QT-PCR (R2=0.985; p<0.01). 
 
 
Table 3.1. Comparison of interassay variation for real-time QT-NASBA and real-time QT-PCRa 
RING STAGES (real-time QT-NASBA)  RING STAGES (real-time QT-PCR) 
Log input nr /ml Average  Range  Log input nr /ml Average  Range 
6 4.67 3.62-  6.16  6 4.51  1.86-  8.75 
5 4.04 1.09-  6.81  5 3.07  0.81-  6.42 
4 3.39 2.68-  4.29  4 4.54  1.17-12.65 
3 4.45 3.19-  6.60  3 2.08  1.13-  4.13 
2 7.95 6.01-  9.78  2 3.87  1.65-  8.75 n=4 
1 9.71 7.48-12.41  1 8.53 4.84-10.84 n=3 
aInterassay variation for ring stage parasite quantification, calculated as standard deviation/mean x 100% for 
each parasite concentration. The average and range were calculated over 3 analyses on different days for real-
time QT-NASBA and over 3 duplicate analyses on different days for real-time QT-PCR. 
 
 
 
 
Figure 3.2. Quantification of parasites in
blood samples taken from a volunteer
during a human experimental P.
falciparum infection. Mean results from
duplicate analyses are shown for real-
time QT-NASBA (open circles) and real-
time QT-PCR (solid squares). The results
of quantification by the two techniques
were significantly correlated (Spearman’s
ρ=0.930, p<0.01). Drug treatment was
given at day 8.3 after infection, when
parasites were detected by microscopy. 
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In vivo samples 
Parasite quantification results for the 13 samples taken during the course of an experimental 
P. falciparum infection are shown in figure 3.2 for real-time QT-NASBA and real-time QT-
PCR. There was a significant correlation between parasite quantification results by real-time 
QT-NASBA and those by real-time QT-PCR (Spearman’s ρ=0.930; p<0.01). 
 
DISCUSSION 
The real-time QT-NASBA quantifies P. falciparum parasites with complete specificity and 
sensitivity, as was previously observed with the ECL-based QT-NASBA [52]. However, the 
advantages of real-time QT-NASBA are that quantification results are obtained more rapidly 
and quantification of high parasite densities is not adversely affected by possible depletion of 
reagents in the amplification process, due to the real-time detection of amplicons. 
Furthermore, results are obtained with less manual handling of samples than the ECL-based 
QT-NASBA requires, and the risk of carryover contamination and of amplicons spreading in 
the laboratory is greatly reduced due to the closed-tube format. 
Comparison of real-time QT-NASBA and real-time QT-PCR for quantification of parasites in 
both control series from in vitro culture and in vivo samples from the human experimental P. 
falciparum infection study shows that the techniques correlate well. Both real-time QT-
NASBA and real-time QT-PCR have a detection limit of 20 parasites/ml of blood. For real-
time QT-NASBA, parasite densities of 10/ml can also be detected, but the detection limit is 
set to 20 parasites per ml of blood, i.e. 1 parasite per blood sample when 50 µl blood 
samples are used. For real-time QT-PCR, detection of 10 parasites/ml of blood is feasible 
but increases the risk of false-negative results, as shown in figure 3.1B and table 3.1. 
When the volumes of blood used for nucleic acid extraction and the amount of extract used 
in both real-time assays are taken into account, the sensitivity of real-time QT-NASBA is 
higher than that of real-time QT-PCR, with absolute detection limits of 0.05 and 1 parasite 
per reaction in QT-NASBA and QT-PCR, respectively. The higher sensitivity of the real-time 
QT-NASBA is attributed to the abundance of ribosomal RNA compared to that of 18S rDNA, 
the target of real-time QT-PCR. 
Although the detection limit of the real-time QT-PCR is 20 parasites/ml of blood [38], in one 
of the parasite dilution series a concentration of 100 parasites/ml of blood repeatedly could 
not be detected by real-time QT-PCR (figure 3.1B and table 3.1). Five independent standard 
parasite dilution series ranging from 5 to 106 parasites/ml of blood, with a total of 58 
measurements, gave correlations with microscopic parasite counts similar to those 
presented in figure 3.1B. In these standard dilution series, both 100 parasites (n=5) and 50 
parasites (n=5)/ml of blood were consistently detected. Considering the consistent results of 
standard dilution series, the negative results for detection of a parasite concentration of 
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100/ml of blood are probably due to a mistake made during the DNA extraction. Just below 
the detection limit, a concentration of 10 parasites/ml of blood cannot be detected in half of 
the samples.  
In the present real-time QT-NASBA, 48 samples can be quantified within 4 hours, including 
RNA extraction, compared to 16 hours when real-time QT-PCR is used. Another advantage 
of QT-NASBA is the ability to use small sample volumes for analysis, enabling the use of 
finger prick blood samples as opposed to venous blood collection and mandatory filtering of 
blood samples for real-time QT-PCR. A recently adapted storage protocol eliminates the 
need to store RNA at -70°C or liquid nitrogen, making the collection of RNA samples during 
field studies more convenient [chapter 4]. The specificity of QT-NASBA for RNA, without the 
need for complicated RNA extraction to remove all genomic DNA from the samples, enables 
further development of the assay for detection of various life stages of P. falciparum [70, 
chapter 2]. The modification of ECL-based QT-NASBA to real-time QT-NASBA also allows 
multiplexing, i.e. the detection of multiple targets within one reaction. Real-time QT-NASBA 
will be a valuable tool for quantification of different developmental stages of P. falciparum in 
studies that e.g. evaluate the effect of control measures or investigate parasite population 
dynamics, epidemiology or the transmission of the disease. 
In conclusion, both the real-time QT-NASBA and real-time QT-PCR are reliable methods for 
quantification of P. falciparum parasites, with low risks of carryover contamination and 
amplicon contamination of laboratory working space. However, in comparison to real-time 
QT-PCR, the results of real-time QT-NASBA can be obtained 12 hours earlier, with a 
relatively easy RNA extraction and the use of finger prick blood samples instead of venous 
blood collection. The development of QT-NASBA for detection of various P. falciparum 
developmental stages and its prospective development into a multiplex assay further 
increase the value of QT-NASBA for malaria studies. Therefore, the use of real-time QT-
NASBA is preferred over that of real-time QT-PCR, especially in studies where large 
numbers of samples need to be quantified at higher levels of sensitivity than microscopic 
detection can provide, such as epidemiological surveys, drug efficacy trials and vaccine 
trials. 
 
ACKNOWLEDGEMENTS 
This work was supported by the Technology Foundation STW (grant no. NFA6009). We 
thank Suzy Spence, Marga vd Vegte-Bolmer and Geert-Jan van Gemert for maintenance of 
the in vitro parasite cultures and synchronisation of parasites and the volunteer who 
participated in the experimental infection study. 
 35 
 
 
 
                                               Chapter   4 
 
 
 
Storage of blood samples with malaria parasites for 
subsequent quantitative RNA analyses at –20 ºC 
 
Petra Schneider1, Gerard Schoone2, Wendy van der Meide2, Marcel Beld3, Robert 
Sauerwein1 and Henk Schallig2 
 
1. Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, the Netherlands 
2. KIT Biomedical Research, Royal Tropical Institute, Amsterdam, the Netherlands 
3. Laboratory of Clinical Virology, Academic Medical Centre, University of Amsterdam, the Netherlands 
 
 
 
 
 
 
 
 
 
Chapter 4 
 36 
ABSTRACT 
Storage of blood samples in guanidium isothiocyanate (GuSCN) lysis buffer and subsequent 
nucleic acid isolation requires storage of samples at -70ºC to enable reliable quantitative 
analyses of RNA. As many field research stations do not have access to reliable -70ºC 
freezing facilities we have adapted the RNA storage protocol to allow storage at -20ºC. 
Laboratory tests showed no detrimental effects of the new protocol on the quality and 
quantity of both rRNA and mRNA compared to the original protocol of RNA extraction. These 
results show that both rRNA and mRNA are stable for at least 2 months when bound to silica 
dioxide and stored dry at -20°C. The new protocol facilitates the storage and transport of 
blood samples prior to RNA analyses. 
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INTRODUCTION 
Storage of blood samples in guanidium isothiocyanate (GuSCN) lysis buffer prior to nucleic 
acid isolation is a widely used method [61]. For reasons not well understood, the amount of 
RNA decreases in blood samples stored in GuSCN lysis buffer at –20ºC for more than two 
weeks. Samples stored at -70ºC are stable for at least one year and even samples stored at 
4ºC can be used although there is some RNA loss over time [73, 74]. Therefore, samples 
collected for quantitative RNA analyses require storage at –70ºC. Many field research 
stations do not have reliable facilities to store large numbers of samples at –70 °C. As 
storage space at -20°C is often more easily accessible, we tested an adapted protocol to 
store blood samples containing Plasmodium falciparum parasites at -20°C for quantitative 
RNA analyses. This new storage protocol should facilitate collection of RNA samples during 
field studies and allow storage at the field site until transport and further processing. 
 
MATERIALS AND METHODS 
Human blood was spiked with NF54 P. falciparum-infected red blood cells from 
synchronised in vitro cultures [9] to obtain concentrations of 104 and 106 sexual stage 
parasites/ml blood. 50µl aliquots of the spiked blood samples were stored according to the 
original protocol [61] or the new protocol and were processed after 7, 14, 30 and 60 days of 
storage. Original protocol: 50 µl of blood is added to 900µl of GuSCN lysis buffer (120g 
GuSCN in 100 ml 0.1M Tris-HCl, pH 6.4; add 22ml 0.2M EDTA pH8.0 and 2.6g Triton X-
100). After thorough mixing the vial is stored at -70°C. The samples are thawed prior to RNA 
extraction using the standard GuSCN method [61]. The new storage protocol consists of 
partial RNA isolation following the original GuSCN RNA extraction method until the nucleic 
acids are bound to silica dioxide particles. Briefly, 50 µl of blood and 30µl of silica dioxide 
[61] is added to 900µl of GuSCN lysis buffer. After thorough mixing and shaking for 10 
minutes (300 rpm), the vial is centrifuged briefly and the supernatant removed. The nucleic 
acids are bound to silica and stored at -20°C. To complete the RNA extraction, the sample is 
thawed and the GuSCN RNA extraction method resumed. Parasites were quantified by RNA 
detection using quantitative nucleic acid sequence based amplification (QT-NASBA) for 18S 
rRNA [52] and Pfs25 mRNA as described in Schneider et al. [70, chapter 2]. Samples were 
tested in duplicate.  
 
RESULTS AND DISCUSSION 
Results of RNA quantification of in vitro samples stored according to the original and the new 
protocol are presented in table 4.1. Although some variation in quantification occurs, there is 
no significant difference between quantification of samples handled according to the original 
Chapter 4 
 38 
and the new protocol for both concentrations and all time points (p>0.05). The ratio of 
quantification (new/original protocol) is not significantly different from 1.00 at any time point 
and shows no obvious changes over time. Variations in quantification do not seem to be 
biased towards a lower RNA yield for either of the protocols. Due to a limited supply of 
parasites, the study was restricted to 2 parasite concentrations and 2 duplicates per sample. 
When taking into account the variation 8% and 10% as observed in quantification of fresh 
blood samples for 18S rRNA and Pfs25 mRNA respectively, we could not observe a 
significant difference in quantification of RNA stored by the two protocols. However, more 
replicates per sample may allow a more accurate statistical comparison between the two 
protocols with sufficient power.  
 
 
 
 #Pf/ml  day 7 day 14  day 30  day 60 
18S 104 1.12 0.96 0.95 1.12 
 106 1.00 0.94 0.98 0.93 
Pfs25 104 0.97 1.18 1.01 1.02 
 106 0.99 0.97 0.98 0.88 
 
To test the susceptibility of RNA, stored according to the new protocol, for temporary 
defrosting, samples were thawed and kept at either +4°C or room temperature for 3 and 7 
days. Results showed that temporary defrosting had a detrimental effect mainly on Pfs25 
mRNA quantification at the lower concentration. Transport at +4°C or room temperature is 
therefore not recommended if quantitative RNA analyses need to be performed. However, 
accidental defrosting as a result of e.g. failure of electricity supplies or delays in transport 
does not imply that all data are lost: qualitative analyses are still possible as well as 
quantitative analyses if taking into account that low concentrations of mRNA may have been 
lost due to insufficient care of sample storage. All samples in these experiments were 
defrosted only once; repeated thawing could affect the quality of RNA and should be 
avoided if possible. 
These preliminary tests were confined to a limited number of replicates and did not allow 
solid statistical testing. Further studies, including more replicates per sample, are currently 
performed to confirm the preliminary results presented here and may allow statistical 
comparison between the two protocols with sufficient power. Since the protocol suggested in 
this study still requires some processing of samples in the field, further experiments will also 
test the quality of dried blood samples on filter paper for quantitative RNA analysis. 
Additionally, these experiments test the quality and quantity of both mRNA and rRNA of 
Table 4.1. Ratio of quantification of 2 samples by the new/ original protocol calculated as: (1new + 2new)/(1orig +
2orig). Ideally the ratio should be 1.00 but when including a variation of 8% and 10% as observed in quantification
of fresh blood samples for 18S rRNA and Pfs25 mRNA respectively, the ratio can vary between 0.85-1.17 for 18S
and between 0.81-1.22 for Pfs25. 
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Plasmodium falciparum, Leishmania and Trypanosoma parasites to confirm effects of 
storage on RNA in different parasite species. 
In conclusion, the new storage protocol gave similar results in quantitative rRNA and mRNA 
analyses compared to the originally used storage protocol at -70°C at both of the tested 
parasite concentrations. This suggests that both rRNA and mRNA are stable for at least 2 
months when bound to silica and stored ‘dry’ at -20°C. The extraction protocol is easy and 
requires standard laboratory equipment only.  
The new storage protocol was used for blood samples collected during a field research study 
in western Kenya and proved to be practically feasible and more convenient than 
maintenance of -70ºC freezing facilities. Presence of both rRNA and mRNA at very low 
concentrations was confirmed by quantitative RNA analysis [chapters 5 and 8]. The new 
protocol facilitates the storage and transport of blood samples prior to RNA extraction and is 
a valuable addition to the original protocol during our field research study in Kenya. 
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ABSTRACT 
The effects of drugs on Plasmodium falciparum transmission stages may reduce the spread 
of parasites in the population and contribute to malaria control. Detailed quantitative studies 
on (sub)microscopic gametocytaemia have become feasible with the availability of real-time 
Pfs25 quantitative Nucleic Acid Sequence-Based Amplification (QT-NASBA), which can 
detect gametocyte densities above 20 gametocytes/ml from in vitro cultures.  
Gametocyte dynamics were investigated in children with uncomplicated P. falciparum 
malaria after treatment with sulphadoxine-pyrimethamine (SP) or a combination of SP and 
artesunate (SP+AS), in a 28-days drug efficacy study. 
This study demonstrated that gametocyte prevalence in 873 samples from symptomatic 
Kenyan children was 2.8 times higher by QT-NASBA compared to microscopy. Microscopy-
positive cases showed a significant correlation with QT-NASBA for gametocyte density. At 
enrolment, gametocyte prevalence was 86% by QT-NASBA compared to 22% by 
microscopy. Gametocytes were detected in 97% of children in at least one blood sample and 
in 38% of children in all samples obtained during the 28-days follow-up. Both the risk of 
gametocyte carriage and gametocyte density were considerably higher after treatment with 
SP compared to SP+AS. Gametocyte prevalence and density decreased with time in the 
SP+AS group, but not in the SP-treated children.  
Our data suggest that the potential of malaria transmission remains high even after 
treatment with artemisinin combination therapy, although prevalence and density of 
gametocytes is lower after SP+AS. 
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INTRODUCTION 
Clinical symptoms of malaria are caused by cyclical proliferation of asexual Plasmodium 
parasites in the patient’s red blood cells. Spread of the disease depends on the presence of 
mature sexual stage parasites (gametocytes), which do not replicate or cause clinical 
symptoms, but are essential for transmission from humans to the mosquito vector. 
As measures to prevent malaria are not completely efficient, early treatment of symptomatic 
infections is a major component of malaria control strategies. Drugs are designed to cure 
clinical symptoms and therefore mostly target asexual stages; the impact of drug treatment 
on gametocytes and transmission has long been neglected. Some drugs increase (e.g. 
chloroquine and sulphadoxine-pyrimethamine) or decrease (e.g. artemisinin derivatives) 
gametocyte prevalence [75-78]. Due to increasing resistance to most affordable antimalarial 
drugs, many countries are forced to revise drug treatment strategies. Generally, artemisinin 
combination therapies (ACT) are recommended to replace current first line drugs such as 
chloroquine and sulphadoxine-pyrimethamine (SP). Addition of artemisinin derivatives to 
other antimalarial drugs may protect the other drug from development of resistance. The 
benefit of better cure rates induced by ACT combined with its effect on transmission due to 
its alleged gametocytocidal effects [79] may justify increased costs for treatment. 
The key factors that trigger sexual stage development are not yet well understood. 
Gametocytes are derived only from a small subset of asexual parasites and only a fraction of 
patients develop patent gametocytaemia [6]. However, the limited prevalence of 
gametocytes contradicts the successful spread of malaria and the difficulties to control 
malaria transmission [24]. Recently, a number of studies have addressed the effect of 
antimalarial drug treatment on gametocytes [77, 80-85]. Most of these studies used 
microscopy for detection and quantification of gametocytes, but it has been shown that 
patients without microscopically detectable gametocytes can infect mosquitoes [64, 86] and 
submicroscopic gametocytaemia can be common [39, 65, 66, 87]. Detailed quantitative 
studies on submicroscopic gametocytaemia are now possible with the recently developed 
gametocyte-specific Pfs25 quantitative Nucleic Acid Sequence-Based Amplification (QT-
NASBA) [70, chapter 2]. The assay is performed in real-time, and quantifies mature P. 
falciparum gametocytes in blood samples with a sensitivity of 20-100 gametocytes per 
millilitre of blood. The objective of this study was to investigate the effect of SP and of SP 
plus artesunate (SP+AS) treatment on P. falciparum gametocyte dynamics using Pfs25 real-
time QT-NASBA. 
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MATERIALS AND METHODS 
Real-time Pfs25 QT-NASBA and nucleic acid extraction 
Nucleic acids were extracted from blood samples using the guanidium isothiocyanate 
(GuSCN)/silica procedure as described by Boom et al. [61]. Total parasite load was 
quantified by real-time 18S rRNA QT-NASBA as previously described [107]. Pfs25 mRNA 
QT-NASBA was performed as described by Schneider et al. [70, chapter 2] with some 
adjustments to enable real-time detection. Briefly, real-time QT-NASBA for Pfs25 mRNA 
(Genbank accession number AF193769.1) was performed on a NucliSens EasyQ analyser 
(bioMérieux) using the NucliSens Basic Kit for amplification according to manufacturer’s 
manual at a KCl concentration of 80mM. Reactions were carried out in a total reaction 
volume of 10µl per reaction. Forward primer: 5’-gactgtaaataaaccatgtggaga-3’ (nucleotides 
204-227); reverse primer: 5’-aattctaatacgactcactatagggagaaggcatttaccgttaccacaagtta-3’ (T7 
promoter sequence, linker and nucleotides 338-359); Pfs25 molecular beacon: 5’-TexasRed-
cgatcgcccgtttcatacgct tgtaacgatcg-DABSYL-3’ (molecular beacon stem of 6 paired 
nucleotides and nucleotides 259-278). Time to positivity was calculated, i.e. the time point 
during amplification at which the fluorescence detecting target amplicons exceeded the 
mean fluorescence of three negative controls + 20 standard deviations (SD). The use of a 
standard gametocytes stage V dilution series allowed exact calculation of the number of 
gametocytes present in unknown samples [70, chapter 2]. 
 
Sensitivity and interassay variability 
Blood samples of in vitro parasite culture of P. falciparum NF54 [9] were collected as 
described by Schneider et al. [70, chapter 2], with the exception that internal controls for 
quantification were not added to the samples. Ten-fold dilution series of gametocytes 
ranging from 106 to 10 gametocytes per millilitre of blood were made, nucleic acids extracted 
using the GuSCN/silica procedure [61] and the number of gametocytes was quantified by 
real-time Pfs25 QT-NASBA.  
 
Field study 
A drug efficacy study was performed from October to December 2003 in Mbita, Western 
Kenya, according to the WHO protocol [88]. Mbita is a rural region on the shores of Lake 
Victoria experiencing endemic malaria with seasonal variation in transmission intensity. A 
description of the study site can be found in [89, 90]. Study approval was obtained from the 
ethical and scientific review boards of the Kenya Medical Research Institute (SSC 791).  
In total, 245 children aged 6 months to 10 years with uncomplicated clinical P. falciparum 
malaria confirmed by microscopy (500-100000 parasites/µl) were included in the study after 
their guardians gave informed consent. Children were randomised to receive either SP 
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(Fansidar, Roche, Switzerland; 125mg sulphadoxine and 6.25mg pyrimethamine/5kg as a 
single dose) or SP+AS (Arsumax, Sanofi, France; 20mg/5kg daily for 3 days) treatment. 
Details of randomisation and treatment procedures are described elsewhere [chapter 8]. 
Follow-up was performed under supervision of the study clinician on days 1, 2, 3, 7, 14 and 
day 28 post-treatment and at any time the child showed symptoms of disease. At all 
sampling points, a blood smear for microscopical detection of parasites was made and 
stained with 10% Giemsa. Asexual parasites were counted against 200 leucocytes, 
gametocytes against 500 leucocytes and converted to number of parasites per volume 
assuming 8000 leucocytes/µl blood. Slides were considered negative when no parasites 
were detected after viewing 100 microscopical fields at a 10x100 magnitude. Additional to 
the standard protocol (microscopy), at all sampling times, a small blood sample on filter 
paper was collected for genotyping as well as a blood sample (50 µl) for QT-NASBA, which 
was stored in GuSCN lysis buffer until further analysis. QT-NASBA samples were not 
collected on day 2. Samples for all methods were obtained from the same finger prick.  
 
Statistical analysis 
Statistical analyses were performed in SPSS version 12.0.1 and STATA 7.0. Mann-Whitney 
U test was used for comparisons between groups for continuous variables and Chi-square 
test for discontinuous variables. Relations between results by microscopy and QT-NASBA: 
Spearman correlation and paired t-test. 
Gametocyte prevalence and density after treatment were assessed by QT-NASBA in a 
subset of 118 children, aged 6 months to 5 years, who completed at least 7 days of follow-up 
(age groups of 1, 2, 3, 4 and 5 years consisted of respectively 32, 23, 20, 21 and 22 
children). This group was representative for the entire study group regarding gender (50% 
male), mean weight (13.3 kgs) and mean age (2.8 years). Gametocyte prevalence at 
enrolment was similar between the two treatment groups (Chi square tests, p=0.770 for 
microscopy and p=0.421 for QT-NASBA), as well as total parasite and gametocyte densities 
at enrolment (Mann-Whitney U tests, total parasite density p=0.345 and 0.516; gametocyte 
density p=0.732 and 0.538 for microscopy and QT-NASBA respectively). Logistic regression 
was used to determine the relation of gametocyte prevalence to days after treatment and 
drug treatment (SP or SP+AS), with adjustment for age in years and outcome of drug 
treatment (adequate clinical response or late treatment failure (WHO, 2002)). Odds Ratios 
(OR) were calculated with 95% confidence intervals (95% CI). For gametocyte density, linear 
regression was used with inclusion of the same parameters, but only gametocyte-positive 
samples were used in the analysis. In case of multiple observations per individual, 
Generalised Estimating Equations (Hanley et al., 2003) models (STATA 7.0) were used to 
allow for autocorrelation. 
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RESULTS 
Sensitivity and interassay variation of real-time Pfs25 QT-NASBA 
Eighteen independent gametocyte series from in vitro parasite culture were processed over 
a period of 2 months. Gametocyte densities from 102 to 106 gametocytes/ml could be 
detected consistently with 10 gametocytes/ml being close to the detection limit of 20-100 
gametocytes/ml of blood. Interassay variability (SD/average*100%), including variations in 
culture material and nucleic acid extractions, is below 10% for all measured gametocyte 
densities and is highest for the lower densities (table 5.1). Regression analysis on the 10log 
number of parasites present in the control samples and the resulting time to positivity 
showed a consistently significant correlation (p<0.001) with a correlation coefficient of on 
average 0.98 (range 0.92-0.99). 
For negative controls, blood samples (50 µl) were obtained from 20 malaria-naïve blood 
donors in Nijmegen, the Netherlands and from 10 healthy volunteers at Kenya Medical 
Research Institute, Nairobi, Kenya with no recent history of malaria. The 30 blood samples 
were all confirmed negative by Pfs25 QT-NASBA.  
 
Table 5.1. Interassay variability (SD/average*100%) for real-time Pfs25 QT-NASBA in 18 independent dilution 
series from in vitro cultured gametocytes. 
Log gct/ml TTP Standard deviation Interassay variability 
6 46.60 1.95 4.2% 
5 53.48 3.32 6.2% 
4 64.56 4.26 6.6% 
3 72.70 5.03 6.9% 
2 84.06 6.29 7.5% 
1* 89.85 8.33 9.3% 
Log gct/ml: 10log of the number of gametocytes/ml of blood originally determined by microscopy and diluted. TTP: 
Average time to positivity for Pfs25 QT-NASBA for each gametocyte concentration. * Calculations for 8 
measurements only, 10/18 were below the detection limit and excluded from analysis 
 
Field study, comparison microscopy and QT-NASBA for gametocyte quantification 
In total, 873 samples obtained during the drug efficacy study in Mbita were quantified for P. 
falciparum gametocytes both by microscopy and by Pfs25 QT-NASBA. Figure 5.1 shows 
that 72% of the samples were positive for gametocytes by QT-NASBA, while gametocytes 
were detected in only 26% of the blood smears by microscopy. In 54% of the positive 
samples, gametocyte densities observed by microscopy were close to the detection limit with 
1 gametocyte/500 leucocytes. The Pfs25 QT-NASBA confirmed 92% of the microscopically 
positive samples; 65% of the microscopically gametocyte negative samples was positive in 
the QT-NASBA with a geometric mean of 6.0*102 gametocytes/ml (IQR 1.7*102–2.1*103), 
which is well below the detection limit of microscopy (1.6*104 gametocytes/ml). In total, 
inconsistent results between Pfs25 QT-NASBA and microscopy were shown in 33/873=3.7% 
of the samples. Quantification of gametocytes by Pfs25 QT-NASBA and microscopy showed 
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a statistically significant correlation (Spearman correlation, ρ=0.452, p<0.001). However, for 
samples with microscopically detected gametocytes, QT-NASBA quantification was 
significantly lower than quantification by gametocyte microscopy (paired t-test, p<0.01). 
 
  
 
Gametocyte dynamics after SP and SP+AS treatment 
A total of 245 children were included in a study comparing treatment efficacy of SP alone 
versus SP+AS [also chapter 8]. A random subset of 118 children was included for QT-
NASBA analysis. Gametocyte prevalence at enrolment was 22% as detected by microscopy 
and 86% by Pfs25 QT-NASBA. In total 97% of all children showed gametocytes at some 
time point and 38% showed gametocytes at all time points during the 28-days follow-up 
period by Pfs25 QT-NASBA. 
The SP+AS treated group (n=55) showed a significantly lower risk of gametocyte carriage 
(OR 0.137; 95% CI 0.065, 0.288) and a reduced gametocyte density (β -0.395; 95% CI -
0.652, -0.139) compared to the SP treated group (n=63) in the Pfs25 QT-NASBA analysis. 
Microscopical analysis showed a less pronounced effect of treatment on prevalence (OR 
0.322; 95% CI 0.185, 0.561) and no statistically significant effect on gametocyte density. 
Since SP and SP+AS showed different effects on gametocytes, data were further analysed 
separately for both treatment groups. Gametocyte prevalence by QT-NASBA significantly 
decreased with time in the SP+AS treated group (OR 0.905; 95% CI 0.877, 0.934) but not in 
the SP group (figure 5.2). Similar results were obtained with microscopy. However, 
microscopy data show a peak in gametocyte prevalence at day 7 after SP treatment that 
was not detected by Pfs25 QT-NASBA (figure 5.2). Gametocyte density decreases 
significantly (β -0.032; 95% CI -0.048, -0.017) after treatment with SP+AS but not after 
treatment with SP, where gametocyte densities peaked at day 7. This is illustrated in figure 
5.3 where the median of gametocyte densities relative to the day 0 density are shown. 
 
Figure 5.1. Percentage of
gametocyte positive samples as
determined by microscopy (MICR)
or Pfs25 QT-NASBA (NASBA) in a
total of 873 samples. 
Chapter 5 
 48 
 
 
 
 
 
 
 
Figure 5.2. Gametocyte prevalence from day 0 to 28 after treatment, calculated by microscopy (black bars) and 
Pfs25 QT-NASBA (grey bars) for SP monotherapy and SP+AS combination therapy. Error bars indicate the 
upper limit of the 95% confidence intervals. 
 
 
 
 
 
 
 
 
 
Figure 5.3. Median QT-NASBA total parasite (hatched bars) and gametocyte (grey bars) densities relative to day 
0 for SP monotherapy and SP+AS combination therapy. 
 
DISCUSSION 
The real-time Pfs25 QT-NASBA is more sensitive for quantification of P. falciparum 
gametocytes as compared to standard microscopy (detection limits of 20-100 and 16000 
gametocytes/ml of blood, respectively). Inconsistent results between gametocyte detection 
by microscopy or Pfs25 QT-NASBA, including both false positive and false negative results, 
occurred in 3.7% of all samples. Similar low percentages of inconsistent results were found 
during a cross-sectional study in Burkina Faso [chapter 6]. The observation that QT-NASBA 
results in lower gametocyte densities compared to microscopy may be explained by an 
overestimation of gametocyte densities by microscopy. Counting of gametocytes against 500 
leucocytes was started only after the first gametocyte has been detected, which introduces a 
positive bias in quantification. 
Over 90% of the microscopically gametocyte-positive in vivo samples from the study in 
Kenya contained low densities of gametocytes (1-5 gametocytes/500 leucocytes). The 
increased sensitivity of gametocyte detection by Pfs25 QT-NASBA revealed high 
prevalences of submicroscopic levels of gametocytes at enrolment and during the 28-days 
follow-up period. This confirms previous studies showing submicroscopic gametocytaemia in 
endemic samples [64, 66, 87, 92, 93]. Almost all children harbour gametocytes at some time 
point during the study and 38% show persistent gametocytaemia during follow-up. This 
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suggests that the majority of children with uncomplicated symptomatic P. falciparum 
infection contribute to the potential infectious reservoir both before and after treatment with 
antimalarial drugs. 
Our data further show that the gametocyte reservoir in symptomatic children may be much 
larger than previously indicated by microscopical analyses. Many gametocyte carriers carry 
very low densities of gametocytes (geometric mean 600/ml) in the circulation. Data suggest 
that gametocyte densities as low as 375 gametocytes/ml of blood can infect Anopheles 
stephensi mosquitoes in membrane feeding experiments [chapter 7]. Therefore, low 
gametocyte densities in vivo may infect mosquitoes, especially when taking into account that 
P. falciparum gametocytes in the peripheral blood may not be homogeneously distributed 
[94, 95]. 
Both gametocyte carriage and higher gametocyte densities are considerably more prevalent 
in the SP group compared to SP+AS. A post-treatment reduction of gametocyte prevalence 
and density over time was present in the SP+AS but not in the SP treatment group. The 
peak gametocyte prevalence at day 7 after SP treatment observed by microscopy confirms 
data from previous studies [29, 75, 85] but was not confirmed by QT-NASBA. In contrast, 
QT-NASBA showed a peak in gametocyte density in the SP group at day 7. This difference 
may be explained as higher gametocyte densities being more likely to be detected by 
microscopical analysis. The peak of gametocyte density at day 7 after SP treatment cannot 
be the result of de novo induction under drug pressure, as gametocyte development takes 
longer than 7 days. This peak may reflect the slower clearance of asexual parasites and 
immature gametocytes after SP treatment compared to SP+AS treatment. These results 
show that data on gametocyte prevalence are highly dependent on the sensitivity of the 
detection method and microscopy is inferior for this purpose. In conclusion, the Pfs25 QT-
NASBA is the preferred technique to detect and quantify P. falciparum gametocytes. The 
use of Pfs25 QT-NASBA in transmission studies provides more detailed data and makes 
studies, especially those with small sample sizes, more efficient. 
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ABSTRACT 
The sexual stages of Plasmodium falciparum play a key role in the transmission of malaria. 
Studies on gametocytes are generally based on microscopical detection but more sensitive 
detection methods for P. falciparum gametocytes frequently detect subpatent gametocytes. 
We have used Pfs25 mRNA QT-NASBA to quantify gametocytes in 412 samples from a 
cross-sectional study in Burkina Faso, covering all age groups, to determine age-related 
patterns in gametocyte carriage and gametocyte density. The QT-NASBA gave estimates of 
gametocyte prevalence 3.3 fold higher than microscopy (70.1% versus 21.4% respectively). 
Prevalence of gametocytes significantly decreased with age. Our data suggest that asexual 
parasite density is primarily responsible for the age-related decrease of gametocyte 
prevalence, possibly due to developing asexual stage immunity. Gametocyte densities also 
decrease with age, primarily due to decreasing asexual parasite densities; only a small but 
significant age effect on gametocyte density may be due to developing sexual stage-specific 
immunity. 
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INTRODUCTION 
Malaria is caused by protozoan parasites of the genus Plasmodium. The life cycle of these 
parasites consists of both asexual and sexual phases occurring in two hosts. Sexual 
reproduction occurs in the invertebrate vector, Anopheles mosquitoes for human malaria, 
while reproduction in the vertebrate host is solely asexual. However, sexual stage 
development starts in the vertebrate host where a proportion of the asexual parasites 
transform into sexual stages called gametocytes. The gametocytes can infect mosquitoes 
and are responsible for ongoing transmission of malaria. Despite the importance of 
gametocytes for the spread of malaria, relatively little is known about sexual stage 
development in comparison to asexual stages that cause disease symptoms. One factor is a 
lack of sensitive detection techniques for gametocytes that are convenient for use in large-
scale studies. 
Until recently, gametocyte detection was based on microscopy, which is rather insensitive 
and inaccurate in quantification of gametocytes in blood samples. Individuals without 
microscopically detectable gametocytes can infect mosquitoes and higher gametocyte 
prevalences are found when larger volumes of blood are counted [93, 96, 97, 98]. More 
sensitive detection methods for Plasmodium falciparum gametocytes such as the Pfs25 or 
Pfg377 reverse transcriptase polymerase chain reaction [39, 65] are able to detect 
submicroscopic gametocytaemias [66, 87], which can be quantified by Pfs25 mRNA QT-
NASBA [chapter 2, chapter 5]. The Pfs25 QT-NASBA has a detection limit of 20-100 
gametocytes per ml of blood and the high throughput format allows its use in large 
epidemiological studies. A previous study with Pfs25 QT-NASBA showed very high 
prevalence of gametocytes in symptomatic children in Kenya [chapter 5]. The objective of 
this study was to determine submicroscopic levels of gametocytes in a different 
epidemiological setting. We have used Pfs25 QT-NASBA to quantify gametocytes in 412 
samples from a cross-sectional study in Burkina Faso, covering all age groups and 
determined age-related patterns in gametocyte carriage and density.  
 
MATERIALS AND METHODS 
Field study 
The study area and population have been described in detail elsewhere (Ouédraogo et al., 
submitted). Briefly, the study was conducted in 6 small rural villages 30 kilometres north of 
Ouagadougou, Burkina Faso. Health care facilities are equally distributed in the six villages. 
Residents live by subsistence farming in a Sudanese Savannah area with seasonal 
holoendemic malaria. Malaria transmission is highest in the wet season from June to 
December and peaks around September. P. falciparum is responsible for 90% of malaria 
infections with Anopheles gambiae and A. funestus as major vectors [99].  
Chapter 6 
54 
A cross-sectional survey was carried out at the end of the transmission season (December 
2003) at which time 412 villagers of all ages were enrolled. Adults and children of both sexes 
were randomly included by order of arrival until a minimum number of 10 individuals per age 
group with informed consent were included. A finger prick blood sample was taken from all 
participants. Thick and thin blood films were made, air-dried and stained with 5% Giemsa. 
For collection of nucleic acids, 100 µl of blood was mixed with 900 µl of L6 lysis buffer and 
stored for RNA extraction. Most participants were asymptomatic for malaria; only 7% had a 
body temperature of over 37.5 °C and were treated with chloroquine according to the 
national policy. The study received ethical approval of the Ministry of Health of Burkina Faso. 
 
Microscopic detection of P. falciparum parasites 
Samples were considered negative if no parasites were detected in 100 fields (10x100 
magnification). Both asexual stage and gametocyte densities were simultaneously assessed 
by counting against 500 leucocytes in the thick smear. The lower limit of microscopy for 
gametocyte quantification was therefore evaluated to 16 gametocytes/µl of blood. Parasite 
counts were converted to numbers of parasites per µl by assuming a standard count of 8000 
leucocytes/µl of blood. Each sample was read independently by two microscopists. A third 
reader was involved when the difference between the readers exceeded 30% and in such a 
case the median reading was used.  
 
Real-time QT-NASBA and nucleic acid extraction 
Nucleic acids were extracted from blood samples using the guanidium isothiocyanate 
(GuSCN)/silica procedure, described by Boom et al. [61]. 18S rRNA real-time QT-NASBA for 
quantification of total parasite was performed as described in Schneider et al. [chapter 3]. 
Pfs25 mRNA QT-NASBA was performed as described in Schneider et al. with several 
adjustments to enable real-time detection [chapter 5]. Briefly, real-time QT-NASBA for Pfs25 
mRNA (Genbank accession number AF193769.1) was performed on a Nuclisens EasyQ 
analyser (bioMérieux) using the Nuclisens BasicKit for amplification according to 
manufacturer’s instructions at a KCl concentration of 80mM. Reactions were performed in a 
total reaction volume of 10 µl per reaction. Forward primer: 5’-gactgtaaataaac catgtggaga-3’; 
reverse primer: 5’-aattctaatacgactcactatagggagaaggcatttaccgttaccacaagtta-3’; Pfs25 
molecular beacon: 5’-TexasRed-cgatcgcccgtttcatacgcttgtaacgatcg-DABSYL-3’. For 
quantification, time to positivity is calculated, i.e. the time point during amplification at which 
the fluorescence detecting target amplicons becomes higher than the mean fluorescence of 
3 negative controls +20 standard deviations. The use of a standard gametocytes stage V 
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dilution series allows exact calculation of the number of gametocytes present in unknown 
samples [70, chapter 2]. 
 
Data analysis 
Statistical analyses were performed in SPSS 12.0.1. Because parasitological parameters, 
including total parasite and gametocytes densities, were not different between the 6 villages 
(data not shown), samples were pooled for analyses. Spearman correlation was used to 
determine correlation between results of microscopy and QT-NASBA. A 10log(x+1) 
transformation was applied to both asexual parasite and gametocyte counts to allow 
negative samples in the analysis. Geometric mean of gametocyte density was calculated for 
gametocyte positive samples and for all samples, including the negatives. To determine the 
relation to age group and asexual parasite density, logistic regression was used for 
gametocyte prevalence and linear regression for gametocyte density. The age range was 
very large and therefore we have analysed age group as a categorical variable in 
comparison to the oldest age group of 25+ years (adults). With such analyses, a decrease of 
the correlation coefficient with increasing age group indicates a negative relation between 
age group and the parameter under investigation. 
 
RESULTS 
Comparison QT-NASBA and microscopy for gametocyte detection 
Blood samples for QT-NASBA analysis were collected randomly from 412 individuals with 
mean age of 17.5 yrs (range 2-83 years) after informed consent. All participants were 
assigned to age groups <5 years (n=79), 5-9 years (n=97), 10-14 years (n=78), 15-24 years 
(n=71) and ≥ 25 years (n=87). Pfs25 mRNA QT-NASBA confirmed 92% (81/88) of samples 
gametocyte positive by microscopy with a geometric mean density of 3.90*103 (IQR 
5.11*102-2.72*104). In general, gametocyte densities detected by microscopy were close to 
the microscopical detection limit with 1 gametocyte/500 leucocytes counted in 51.1% of 
these samples. The more sensitive QT-NASBA detected gametocytes in an additional 208 
samples with a geometric mean density below the detection limit of microscopy (1.98*103; 
IQR 3.95*102-9.60*103). 
 
Gametocyte prevalence 
Detection of gametocytes by Pfs25 real-time QT-NASBA considerably increased gametocyte 
prevalence from 21.4% (microscopy) to 70.1%. Total parasite and gametocyte prevalence as 
detected by the two methods are shown for all age groups in figure 6.1. The detection of 
total parasite prevalence and gametocyte prevalence were higher by QT-NASBA compared 
to standard microscopy. A decrease of P. falciparum prevalence with age was found by 
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microscopy but not by QT-NASBA, indicating that parasite densities in adults were merely 
reduced to submicroscopic levels. Gametocyte prevalence was negatively associated with 
age and 3.2-3.8 fold higher in the 3 youngest age groups (0-15 years) compared to that in 
adults (25+ years) by QT-NASBA analyses (table 6.1A). For microscopy this was 1.7-1.9 fold 
higher (data not shown). 
Asexual parasite densities detected by microscopy decrease significantly with age 
(Ouédraogo et al., submitted). Because gametocytes are derived from their asexual 
progenitors, it is important to separately detect the effects of age on asexual parasites and 
on gametocytes. Therefore, the asexual parasite density was included as an explanatory 
variable in the analyses of age-related decrease of gametocyte prevalence. After adjustment 
for asexual parasite density, no significant decrease of gametocyte prevalence, detected by 
either QT-NASBA (table 6.1A) or microscopy (data not shown) was found with increasing 
age. A significant positive association was shown between asexual parasite density and 
gametocyte prevalence (OR=1.27; 95% CI 1.16, 1.38; p<0.001 for QT-NASBA (table 6.1A); 
OR=1.12; 95%CI 1.01, 1.25; p=0.040 for microscopy). These data suggest that the age-
related decrease of gametocyte prevalence is probably the result of decreasing asexual 
parasite densities. 
 
A        B 
 
 
 
 
 
 
 
 
 
Figure 6.1: Parasite prevalence for the different age groups, calculated by QT-NASBA (A) and microscopy (B). 
Solid bars represent total parasite prevalence, including asexual parasites and gametocytes. Open bars 
represent gametocyte prevalence. 
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Table 6.1: Effect of asexual parasite density on age distribution of gametocyte carriage and gametocyte density 
measured by QT-NASBA. Results of statistical analyses are presented with (right column) and without (left 
column) adjustment for asexual parasite densities. 
 
A. Gametocyte prevalence without adjustment  with adjustment  
n OR a (95% CI) P-value  OR b (95% CI) P-value 
Asexual density       1.27 (1.16-1.38) 0.000 
Age group <5 79 3.16 (1.61-6.20) 0.001  1.53 (0.73-3.24) 0.262 
  5-9 97 3.83 (2.00-7.37) 0.000  1.86 (0.90-3.83) 0.094 
  10-14 78 3.35 (1.69-6.63) 0.001  1.85 (0.89-3.88) 0.101 
  15-24 71 1.52 (0.80-2.88) 0.197  1.05 (0.53-2.08) 0.884 
  ≥25 87 1.0c    1.0 c 
B. Gametocyte density d  
n Beta a (se(Beta)) P-value  Beta b (se(Beta)) P-value 
Asexual density       0.18 (0.03) 0.000 
Age group <5 79 1.11 (0.26) 0.000  0.50 (0.28) 0.071 
  5-9 97 1.19 (0.25) 0.000  0.59 (0.27) 0.027 
  10-14 78 1.02 (0.27) 0.000  0.53 (0.27) 0.053 
  15-24 71 0.45 (0.27) 0.098  0.16 (0.27) 0.556 
  ≥25 87 0.0 c    0.0 c   
C. Gametocyte density in Pfs25 NASBA positive gametocyte carriers e,f 
   n Beta a (se(Beta)) P-value 
Age group <5 61 0.406 (0.19) 0.037 
  5-9 78 0.369 (0.19) 0.046 
  10-14 61 0.248 (0.19) 0.201 
  15-24 44 0.213 (0.21) 0.309 
  ≥25 45 0.0 c 
a Crude values of odds ratio (OR) and Beta; b OR and Beta adjusted for 10Log asexual parasite density; CI 
confidence interval; se standard error; c age group ≥25 years was used as reference group; d All samples e 
Samples from Pfs25 QT-NASBA positive gametocyte carriers. f Adjustment for asexual density was not 
significant with β=0.023, se(β)=0.026 and P-value 0.378 
 
Gametocyte density 
Figure 6.2 shows that gametocyte densities as well as the asexual parasite densities 
decrease with age. Linear regression analyses showed a significant negative effect of age 
on gametocyte density detected by both QT-NASBA (table 6.1B) and microscopy (data not 
shown). Individuals over 15 years of age carried lower gametocyte densities than children 
aged 0-15 years. When asexual parasite density was included as a covariate, a significant 
positive relation was found with gametocyte density by both QT-NASBA (β=0.18; 
se(β)=0.033; p<0.001 (table 6.1B)) and microscopy (β=0.076; se(β)=0.036; p=0.036). After 
this adjustment for asexual parasite density, in the age-related difference in gametocyte 
density has mostly disappeared although a trend remained. These results suggest that the 
age-related decrease of gametocyte densities may depend on asexual density as shown for 
gametocyte prevalence. 
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Calculations of mean gametocyte densities are influenced by gametocyte prevalence if 
gametocyte-negative samples are included. Therefore, any factor that influences gametocyte 
prevalence may have been included in the analysis, without necessarily having a direct 
relation to gametocyte density. To avoid the risk of incorporating such indirect effects, the 
analyses were repeated in only QT-NASBA gametocyte-positive samples. Asexual density 
still tended to decrease with age, although the relation was not significant (p=0.378). 
However, QT-NASBA gametocyte densities still decreased slightly with age. Table 6.1C 
shows that the 2 youngest age groups (<10 years) carry significantly higher gametocyte 
densities compared to adults. This effect of age is independent of asexual parasite density. 
Such an age effect was not significant for microscopy, with or without asexual parasite 
density as a covariate.  
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
Pfs25 real-time QT-NASBA showed an overall gametocyte prevalence of 70.1% during a 
cross-sectional study at the end of the rainy season in Burkina Faso, which is higher than in 
studies based on microscopy [64, 100, Ouédraogo et al. (submitted)]. Although the 
additionally detected gametocyte carriers in general have very low gametocyte densities, the 
potential contribution of this group to the infectious reservoir should not be ignored [chapter 
7]. Therefore, transmission studies based on mosquito feeds with random population 
samples [64, 86, 101] will give a more adequate estimation of population-wide transmission 
potential than studies based on microscopy [100, 102-104]. 
Age-related decreases in both asexual parasites and gametocytes have been shown before 
[29, 64, 86, 90, 100, 105]. Such relations may be the result of developing immunity to 
asexual and sexual stages of Plasmodium falciparum over time. In this study, the age-
dependent decrease of asexual parasites suggests the development of asexual stage 
immunity. Gametocyte prevalence and densities also decreased with age. As these stages 
are formed from their asexual progenitors, this may be the result of a lower availability of 
Figure 6.2: Mean parasite
densities for different age
groups, calculated for all
samples. Solid bars represent
asexual parasite density
measured by microscopy.
Striped bars represent
gametocyte density measured
by QT-NASBA. Numbers of
individuals per group are
presented on top of bars.
Error bars indicate standard
deviations. 
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asexual progenitors (asexual stage immunity), of cross-stage immunity [106] or of sexual 
stage-specific immunity. Our results show that the relation between age and both 
gametocyte prevalence and density depends primarily on asexual parasite density, 
suggesting that asexual or cross-stage stage immunity may be the important determinant. 
This effect may obscure direct influences of age, i.e. anti-gametocyte immunity. We have 
adjusted for this effect in two different ways. 1) By adjusting for asexual parasite density. 
Although a trend was seen, age-related decreases in gametocyte density were non-
significant after this adjustment. However, as a result of adjustment with highly variable 
asexual parasite densities, larger samples sizes may be required to obtain significant 
relationships. 2) By selecting only Pfs25 QT-NASBA positive samples. The influence of 
asexual parasite density was reduced to insignificant levels in this selection, while an age-
related decrease in gametocyte density was still seen. This decrease of gametocyte 
densities with age, unaffected by asexual parasite densities, may be the result of anti-
gametocyte immunity. However, the overall age-related, and probably immune-mediated, 
decrease of gametocytes seems to be determined primarily by decreased asexual parasite 
density and only slightly by direct age-effects on gametocytes. 
The influence of asexual parasite density on gametocytes, described above, was based on 
analyses including microscopically counted asexual parasites. Although microscopical 
detection of asexual parasites is more robust than that of gametocytes, more sensitive 
methods like QT-NASBA may also detect subpatent asexual parasites. Ideally we would 
have included asexual parasite density determined by QT-NASBA as a covariate. 
Unfortunately, QT-NASBA is currently available for quantification of total parasite load [107, 
chapter 3] or for gametocytes, but not yet for specific quantification of asexual parasites.  
Our results were obtained with samples collected at the end of the wet season. With a 
marked seasonal transmission in Burkina Faso, we cannot generalise these results to all 
seasons. It is possible that gametocyte prevalence and mean gametocyte densities as well 
as the relations with age vary over time. Therefore, cross-sectional surveys need to be 
conducted in other seasons. 
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ABSTRACT 
Sensitive gametocyte detection by quantitative nucleic acid sequence-based amplification 
(QT-NASBA) has recently shown that gametocyte prevalence in endemic areas is roughly 3 
times higher compared to standard microscopy. This higher frequency is primarily due to 
submicroscopic gametocyte densities in a large proportion of the population and may 
increase the human reservoir that contributes to malaria transmission. The objective of this 
study was to determine the relationship between gametocyte density and mosquito infection 
under laboratory and field conditions. Serial dilutions of laboratory strain NF54 P. falciparum 
gametocytes showed a significant positive association between gametocyte density and the 
proportion of infected mosquitoes in membrane feeding experiments. The lower limit for 
mosquito infection was estimated to be as low as 375 mature gametocytes/ml of blood. In a 
field study in Kenya, blood samples of 100 randomly selected children with clinical malaria 
were fed to mosquitoes 14 days after antimalarial drug treatment using membrane feeding; 
30.1% harboured gametocytes by microscopy and 79.5% by QT-NASBA. A significant 
positive relation was shown between gametocyte density and the proportion of infected 
mosquitoes; 62.0% of the children was infectious to mosquitoes, of whom 69.4% had no 
microscopically detectable gametocytes. The relative contribution to transmission by children 
with microscopically confirmed gametocytes and by children with submicroscopic 
gametocytaemia was both estimated at 45.3% in this study. Our results show that 
transmission from man to mosquitoes is common at gametocyte densities below the level of 
microscopical detection.  
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INTRODUCTION 
The clinical presentation of malaria in endemic areas is determined by the intensity of 
transmission [108, 109]. Key players in transmission are blood-feeding Anopheles 
mosquitoes and the sexual stages of the parasite (gametocytes), present in the peripheral 
blood of the infected human host. Gametocytes can be ingested by mosquitoes taking a 
blood meal and subsequently develop into infectious forms in the mosquito’s salivary glands 
that can infect the next human host when the mosquito takes another blood meal. 
Transmission studies are generally based on experiments testing the infectivity of malaria-
infected individuals to mosquitoes. Previously, these studies relied on microscopical 
detection of gametocytes, which is relatively insensitive [110] with detection and 
quantification limits of 5 and 16 gametocytes/µl of blood respectively. This was often not 
considered a constraint because transmission below these densities was considered rare or 
even impossible [93]. The theoretical threshold for mosquito infection is estimated at 1 male 
and 1 female fertile gametocyte per mosquito blood meal. With the generally female-biased 
gametocyte sex ratio of Plasmodium [22, 111, 112] this means that on average more than 2 
gametocytes have to be ingested by the mosquito to initiate sporogonic development. The 
likelihood of mosquito infection can be expected to increase proportionally with increasing 
gametocyte density. However, this relation remains equivocal. A positive relation between 
microscopic gametocyte density and the proportion of infected mosquitoes was detected in 
experimental [113-116] and natural [114, 115, 117-121] P. falciparum and P. vivax 
infections. In contrast, other studies only found a weak relation [6, 64, 122, 123] or no 
relation at all [93, 124, 125]. Several studies report mosquito infections by individuals without 
patent gametocytaemia [64, 86, 92, 116, 120, 121, 123, 124], suggesting that the threshold 
of gametocyte density for mosquito infection may be below the microscopic detection limit.  
Recently, the application of molecular techniques for the detection [39, 65] and quantification 
[chapter 2, chapter 5] of gametocytes have shown that that submicroscopic gametocyte 
densities are common [66, 87, chapters 5 and 8]. In this study we use quantitative nucleic 
acid sequence based amplification (QT-NASBA) to determine the relation between P. 
falciparum gametocyte density and the infectiousness to mosquitoes under laboratory and 
field conditions. 
 
MATERIALS AND METHODS 
Infectiousness of cultured gametocytes 
Plasmodium falciparum NF54 gametocytes were obtained from in vitro culture as described 
in Ponnudurai et al. [9]. Two experiments were performed, the first one with mature 
gametocytes, the second with synchronised mature gametocytes. Gametocytes were 
quantified microscopically and serial dilutions were made in whole blood to obtain 
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gametocyte dilutions at approximately 50% haematocrit ranging from 3.3*102 to 7.0*104 
(experiment 1) and from 9.6*102 to 8.7*104 gametocytes/ml (experiment 2). Of all dilutions, a 
50 µl sample was stored at -70ºC for subsequent quantification of gametocytes by real-time 
QT-NASBA. All dilutions were fed through a membrane feeding system to 50 (experiment 1, 
n=7 dilutions) or 100 (exp. 2, n=8) female Anopheles stephensi mosquitoes [126]. After the 
feed, mosquitoes were kept at 26ºC, 80% relative humidity, on glucose until dissected in 1% 
mercurochrome for microscopical assessment of oocyst infection on days 7-9. 
 
Infectiousness of naturally infected children 
Membrane feedings were conducted in children naturally infected with P. falciparum malaria 
in Mbita, Suba District, western Kenya, 14 days after treatment with antimalarial drugs. 
Details of the study can be found elsewhere [chapter 8]. The study protocol was approved by 
the scientific steering committee and ethical review committee of the Kenya Medical 
Research Institute (SSC No. 791). Briefly, children with uncomplicated malaria with a mono-
infection of P. falciparum at a density of at least 500 parasites/µl were enrolled and 
randomised to treatment with sulphadoxine-pyrimethamine monotherapy (SP), SP plus 
artesunate, SP plus amodiaquine or artemether-lumefantrine (CoArtem). On day 14 after 
treatment, membrane feedings were carried out with blood from 100 children, regardless of 
microscopic gametocytaemia. Venous blood samples of 3 ml were obtained from children 
older than 2 years whose parent or guardian gave specific consent for the procedure. From 
each blood sample included in the membrane feedings, 50µl was used for nucleic acids 
extraction for gametocyte detection in QT-NASBA. Each blood sample was fed to 
approximately 150 locally reared 4 to 5-day-old female Anopheles gambiae s.s. mosquitoes 
via an artificial membrane attached to a water-jacketed glass feeder maintained at 37ºC. 
After 10 to 15 minutes, fully fed mosquitoes were selected and kept at 27-29ºC for 7 days on 
glucose (10%) until midguts were dissected in 2% mercurochrome. The midguts were 
examined microscopically for oocysts. For each experiment, exactly 30 mosquitoes were 
dissected.  
 
Gametocyte detection by Pfs25 QT-NASBA 
Quantification of gametocytes by real-time Pfs25 mRNA QT-NASBA was performed as 
described in chapter 5. Briefly, nucleic acids were extracted from the blood samples using 
the guanidium isothiocyanate/silica procedure as described by Boom et al. [61]. QT-NASBA 
was performed on a NucliSens EasyQ analyser (bioMérieux) using the NucliSens Basic Kit 
for amplification according to manufacturer’s manual at a KCl concentration of 80mM in a 
total reaction volume of 10 µl per reaction. Primer and probe sequences are presented in 
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chapter 5. The number of gametocytes is calculated in relation to a standard gametocyte 
stage V dilution series, using the time point of amplification at which the fluorescence 
detecting target amplicons exceeded the mean fluorescence of three negative controls + 20 
standard deviations [70, chapter 2]. 
 
Data analyses 
Statistical analyses were carried out in SPSS version 12.0 and STATA 9. The relation 
between the log-transformed density of gametocytes and the percentage of infected 
mosquitoes was quantified by regression coefficients of linear regression models. 
Regression coefficients β with 95% confidence intervals (95% CI) were presented. 
Proportions were compared using the chi-squared statistic, the trend in proportions with the 
Cochran-Armitage test for trend. Parasite densities were analysed after log-transformation. 
Normally distributed continuous variables were compared using Student t-test. 
 
RESULTS 
Infectiousness of cultured gametocytes 
The percentage of infected mosquitoes was significantly associated with gametocyte density 
from in vitro culture in the first experiment (β=9.8, 95% CI 0.7-19.0, p=0.04)(figure 7.1A) as 
well as the second experiment (β=7.3, 95% CI 4.4-10.1, p=0.001)(figure 7.1B). The range of 
confidence intervals is smaller in the second experiment, likely as a result of synchronisation 
of gametocytes. Figure 7.1 shows that mosquito infections become less likely below a 
density of approximately 800 gametocytes (experiment 1) or 375 mature gametocytes 
(experiment 2) per ml of blood, where the trend line crosses the X-axis. 
 
A       B 
 
 
 
 
 
 
 
 
Figure 7.1: Relation between gametocyte density and mosquito infection for the mosquito feeding experiments 
using dilutions of in vitro cultured P. falciparum gametocytes in experiment 1 (A) and synchronised mature 
gametocytes in experiment 2 (B). 
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Infectiousness of naturally infected children 
A total of 100 membrane feedings were successfully carried out in children with a median 
age of 2.8 (interquartile range 2-4) years. At the time of membrane feedings 25.0% (25/100) 
of the children harboured microscopically detectable gametocytes and 75.0% (75/100) were 
gametocyte positive by Pfs25 QT-NASBA. A total of 62.0% of the children was infectious to 
mosquitoes, of whom 69.4% (43/62) had no microscopically detectable gametocytes. There 
was a weak but significant positive relation between Pfs25 QT-NASBA gametocyte density 
and the percentage of infected mosquitoes (β=1.3, 95% CI 0.7-2.0, p<0.001; figure 7.2). 
Eight children were infectious to mosquitoes with Pfs25 QT-NASBA negative.  
 
 
 
Figure 7.2: Mosquito feeding experiments on naturally infected Kenyan children. Closed triangles represent 
individual membrane feeding experiments. 
 
The infectiousness of submicroscopic gametocyte carriers 
The relations between gametocyte density and mosquito infection show that submicroscopic 
gametocytaemia can contribute to transmission in the field. The membrane feedings allow 
quantification of the contribution of submicroscopic gametocytaemia to transmission. The 
proportion of infectious children and, in particular, the proportion of infected mosquitoes, was 
highest in those with microscopically detectable gametocytes, where Pfs25 QT-NASBA 
indicated the highest gametocyte density (table 7.1). The proportion of infectious children 
was lower in children without microscopically detected gametocytes and lowest in children 
who were negative in both microscopy and Pfs25 QT-NASBA (Cochran-Armitage test for 
trend, p=0.001). The same trend was observed for the proportion of infected mosquitoes 
(Cochran-Armitage test for trend, p<0.001). Importantly, 70% (35/50) of the children with 
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microscopy negative, Pfs25 QT-NASBA positive samples were capable of infecting at least 
one mosquito. Of those children who were gametocyte negative in both microscopy and 
Pfs25 QT-NASBA, 32.0% (8/25) was still infectious to mosquitoes. In general, the 
association between gametocytaemia and the proportion of infectious children in the random 
feeds was weak for microscopy (χ2=2.77, p=0.10) and much stronger for the Pfs25 QT-
NASBA (χ2=12.73, p<0.001). These data show that the contribution of children with 
microscopically confirmed gametocytes and of children with submicroscopic 
gametocytaemias was estimated at 45.3% (table 7.1). 
 
Table 7.1. Gametocyte detection by microscopy and Pfs25 QT-NASBA and the infectiousness to mosquitoes in 
membrane feedings. 
 Gametocyte carriage p-value* 
Microscopy - - +  
Pfs25 QT-NASBA - + +  
Number of samples 25 50 25  
Density, GM (IQR)† - 592.5 (42.0 – 2486.5) 4058.1 (301.0 – 34798.3) 0.007 
Infectious in the experiments1 32.0 (8/25) 70.0 (35/50) 76.0 (19/25) 0.001 
Infected mosquitoes1 1.7 (13/750) 4.1 (62/1500) 8.3 (62/750) <0.001 
Contribution to transmission2 9.5% 45.3% 45.3%  
*P-value for the Student t-test on log-transformed gametocyte density or trend test on proportions. † Geometric 
mean density of gametocytes per ml of blood in the Pfs25 QT-NASBA for positives only. GM: geometric mean. 
IQR: interquartile range. 1 percentage (n/N) 2 The contribution of each group to transmission was based on the 
assumption of equal mosquito exposure of all groups and estimated by multiplying the percentage of infected 
mosquitoes by the proportion of children in that group divided by the percentage of infected mosquitoes by all 
100 children. 
 
DISCUSSION 
In this study, we show that submicroscopic gametocyte densities can efficiently infect 
mosquitoes under both laboratory and field conditions. Although it has previously been 
suggested that submicroscopic gametocyte densities can infect mosquitoes [64, 86, 92, 116, 
120, 121, 123, 124], this is the first study that actually quantified submicroscopical numbers 
and determined the relationship with mosquito infection.  
Data from cultured gametocytes show a clear reduction in the proportion of infected 
mosquitoes with decreasing gametocyte densities. Such a relation has been observed 
before [126, 127] but these experiments were carried out with gametocyte concentrations 
much higher than generally seen in natural infections. With NF54 P. falciparum parasites, 
mosquito infections remain successful with gametocyte densities as low as 375 mature 
gametocytes/ml of blood. The lower limit for mosquito infection from naturally infected 
gametocyte carriers may be even lower. Eight children were infectious to mosquitoes despite 
negative Pfs25 QT-NASBA results. In 8/8samples, 18S ribosomal P. falciparum RNA was 
detected, indicating that asexual and/ or sexual stage parasites are present. Both our in vitro 
and field data suggest that mosquito infection is obtained below the theoretical threshold of 
at least 2 gametocytes/ blood meal. Infection of mosquitoes with lower densities suggests 
that gametocytes may not be randomly distributed in blood samples that were used for both 
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membrane feeding and gametocyte detection. This effect may be even larger under natural 
conditions of transmission, because gametocyte may cluster in capillaries [94, 95]. 
The efficiency of mosquito infection may differ between parasite isolates and vector species 
[128-130]. The use of laboratory-reared mosquito and parasite lines, without natural 
selective pressure, may result in differences in transmission efficiency [131], as may 
unnatural combinations of mosquito species and parasite isolates. For instance, Anopheles 
gambiae was used in Kenya while membrane feeding with NF54 were carried out with the 
unnatural vector Anopheles stephensi. A lower susceptibility to P. falciparum infection of A. 
gambiae compared to A. stephensi was reported before by Vaughan et al. [130]. 
Alternatively, gametocyte fitness may be different between in vitro culture and natural 
infections. Moreover, even synchronised cultures may contain immature stages of 
gametocytes, while blood from naturally infected carriers contains only mature infectious 
stages. However, transmission from NF54 gametocytes from in vitro culture is efficient in our 
lab [126, 127] although it was never tested at such low gametocyte densities before. 
Our data indicate that children with submicroscopic gametocytaemia and microscopically 
confirmed gametocyte carriers contribute equally to transmission. With a 2-fold difference in 
the proportion of mosquitoes infected by children with microscopically detectable (8.3%) or 
submicroscopic gametocytaemia (4.1%), the lower probability of mosquito infection by 
submicroscopic carriers may be counterbalanced by the higher frequency of children with 
submicroscopic gametocytaemias. Similar prevalences of submicroscopic gametocytaemia 
have been detected in cross-sectional studies in areas of lower endemicity in Burkina Faso 
[chapter 6] and Sudan [66], with peak prevalences of 49% and 52%, respectively. 
Fluctuation in submicroscopic gametocyte prevalences [66] and the relation with 
transmission intensity needs to be studied in other areas. However, we feel that our findings 
on the infectiousness of submicroscopic gametocytaemias and the relation between 
gametocyte density and mosquito infection will be of public health importance.  
 
Interventions that target to interrupt transmission will have to reduce gametocyte densities to 
well below the microscopical detection limit to obtain decreased transmission. The success 
rate of such programs may depend not only on the efficiency of the intervention to reduce 
gametocytaemia. If gametocytes are not entirely eliminated by treatment, it may not reduce 
the proportion of infectious individuals but merely the proportion of infected mosquitoes. The 
effect of such interventions on transmission therefore becomes highly dependent on the 
level of mosquito exposure and thus on endemicity levels. The effects of interventions on 
malaria transmission will have to be evaluated using random feeds and more sensitive 
gametocyte detection techniques such as QT-NASBA. 
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ABSTRACT 
Artemisinin based combination therapy (ACT) reduces microscopically confirmed 
Plasmodium falciparum gametocytaemia and mosquito infection. However, molecular 
techniques recently revealed high prevalences of submicroscopic gametocytaemia. Our 
objective was to determine the effect of sulphadoxine-pyrimethamine (SP), SP plus 
amodiaquine (AQ), SP plus artesunate (AS) and artemether-lumefantrine (CoArtem) on 
submicroscopic gametocytaemia and infectiousness. 
Kenyan children (n=528) aged 6 months – 10 years were randomised to the four treatment 
regimens. Gametocytaemia was determined by microscopy and Pfs25 real-time Nucleic Acid 
Sequence-Based Amplification (QT-NASBA). Transmission was determined by membrane 
feedings on day 14 after treatment in microscopically confirmed gametocyte carriers and 
randomly selected children. 
Gametocyte prevalence at enrolment was 89.4% (219/245) as determined by Pfs25 QT-
NASBA and decreased after treatment with SP+AS, SP+AQ and CoArtem. Membrane 
feedings in randomly selected children revealed that the proportion of infectious children was 
up to fourfold higher than expected when based on microscopy and similar for all treatment 
arms. ACT did not significantly reduce the proportion of infectious children but only the 
proportion of infected mosquitoes. 
Submicroscopic gametocyte densities are common after treatment and contribute 
considerably to mosquito infection. The effect of ACT on malaria transmission may be 
moderate and restricted to the duration of gametocyte carriage and the proportion of infected 
mosquitoes.  
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INTRODUCTION 
Antimalarial drug treatment targets the asexual blood stages of Plasmodium falciparum that 
are responsible for clinical disease and death. Sexual stage parasites, gametocytes, which 
do not cause clinical pathology, can also be found in the circulation of infected persons and 
can infect mosquitoes taking a blood meal. After fertilization and further sporogonic 
development, infectious parasites appear in the mosquito salivary gland. With each 
subsequent blood meal, parasites are transmitted to a new person, resulting in the spread of 
malaria in the human population. The majority of currently used antimalarial drugs do not kill 
gametocytes and the effects of drugs on these stages are often ignored in anti malaria drug 
development and policies. 
P. falciparum parasite resistance against antimalarial drugs like chloroquine (CQ) and 
sulphadoxine-pyrimethamine (SP) is rapidly increasing in many areas in sub Saharan Africa. 
This has forced many African countries to abandon monotherapy with these drugs as first 
line antimalarial treatment [132]. Since parasite resistance is less likely to develop under 
combination therapy [133, 134], there is increasing acceptance that combination rather than 
monotherapy is the way forward, with artemisinin as one of the preferred components [132, 
134, 135]. Compared to monotherapy, artemisinin-based combination therapy (ACT) gives a 
higher clinical efficacy [136, 137] in the absence of drug resistance. An additional advantage 
of ACT is the effect on sexual stages, lowering the prevalence and density of post-treatment 
gametocytaemia [27, 75, 136] and subsequent mosquito infection [75, 78, 138]. ACT may 
reduce malaria transmissibility at population level [27, 139] and the specific reduction of the 
transmission of resistant parasite strains [27, 80, 139] further suggests that ACT may 
counteract the spread of drug resistance. 
In contrast to asexual parasites, gametocytes often circulate at such low densities that they 
may not be detected by standard microscopy [110, 140, 141]. The use of Pfs25 mRNA real-
time nucleic acid sequence-based amplification technique (QT-NASBA) [70, chapter 2] 
indeed recently revealed that a large proportion of children with symptomatic malaria 
harbour submicroscopic numbers of gametocytes both before and after antimalarial drug 
treatment [chapter 5]. 
Our objective was to determine clinical efficacy, gametocyte carriage rates by QT-NASBA 
[70, chapter 2] and post-treatment infectiousness to Anopheles gambiae mosquitoes in 
Kenyan children treated for uncomplicated malaria with drug regimens that are currently in 
use or considered in national guidelines in different African countries. These regimens 
include SP monotherapy, SP plus amodiaquine (AQ), SP plus artesunate (3 days) and 
artemether-lumefantrine (CoArtem) [132, 137]. 
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MATERIALS AND METHODS 
This study was conducted in the periods October to December 2003 and 2004 in Mbita, a 
rural village on the shores of Lake Victoria in Suba District, western Kenya. The main 
malaria vectors in the area are Anopheles gambiae, A. funestus, and A. arabiensis. Malaria 
transmission is high and perennial with parasite prevalences in the human population 
ranging from 24.4% to 99.0% [142]. Generally, the rainfall pattern is bimodal, with a long 
rainy season between March and May, and a short rainy season from October to December. 
The study protocol (SSC No. 791) was approved by the Scientific Steering Committee and 
Ethical Review Committee of the Kenya Medical Research Institute. Written informed 
consent was obtained from a parents of guardian for each child. 
 
Study population and treatment 
Study subjects were recruited at the clinic of the ICIPE Mbita Point Field Station and came 
from an area of approximately 10 kilometres around the ICIPE compound. Children aged 6 
months to 10 years with a temperature >37.5Cº or a history of fever and with P. falciparum 
mono-infection at a density greater than 500 parasites/µl were eligible for recruitment. 
Exclusion criteria were: inability to take drugs orally, known hypersensitivity to any of the 
drugs given, reported treatment with antimalarial chemotherapy in the past 2 weeks, 
evidence of chronic disease or acute infection other than malaria, domicile outside the study 
area and signs of severe malaria. Patients were randomly allocated to receive one of the 
four treatment regimes: (i) sulphadoxine (25 mg/kg) and pyrimethamine (1.25 mg/kg) as a 
single dose (SP; Fansidar®, Roche, Switzerland) plus placebo once daily for three days 
(Organon, the Netherlands); (ii) SP plus artesunate (AS), 4 mg/kg once daily for three days 
(Arsumax®, Sanofi, France); (iii) SP plus amodiaquine (AQ), 10 mg/kg once daily for three 
days (Camoquine®, Pfizer, Senegal) or (iv) CoArtem® (artemether-lumefantrine, Novartis 
Pharma, Switzerland), administered as ½ tablet (20 mg artemether, 120 mg lumefantrine) 
per 5 kg body weight in the six-dose regimen: at enrolment and 8, 20, 32, 44, 56 hours 
(±90min) after the initiation of treatment.  
Children were randomised to SP and SP+AS in 2003 and to SP, SP+AS, SP+AQ and 
CoArtem in 2004. Patient numbers were not exactly equal for all groups for several reasons. 
At the time of the study CoArtem was not recommended for children below 10 kg of 
bodyweight. In addition, the six-dose regimen required treatment at the child’s home. Only 
children over 10 kg and residing less then 5 km from the clinic, to allow supervised treatment 
at home, were therefore eligible for randomisation to CoArtem. This resulted in a smaller 
number of children in this treatment arm.  
The numbers for SP and SP+AS are largest because the relevance of random feeding 
experiments became evident in the latter part of data collection in 2004. For these 
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experiments, an additional number of children had to be randomised to SP monotherapy and 
SP+AS.  In addition to the number of children treated with these drugs in 2003 (n=245), 81 
children were therefore randomised to SP and SP+AS in the ratio (1:2). This ratio was 
chosen to facilitate the comparison between SP+AS and CoArtem where parasitological 
differences were expected to be smallest.  
Treatment was administered by staff at the recruitment clinic (for SP, SP + AQ and SP + AS) 
or at the recruitment clinic for the first dose and by field assistants at the child’s home for the 
subsequent doses (for CoArtem). All medication was given with local fatty food (mandazi) to 
facilitate absorption. Each child was observed for 20 minutes after treatment, a replacement 
dose was given in case of vomiting. Repeated vomiting led to exclusion from the study. 
Paracetamol (10 mg/kg) was given until symptoms had subsided.  
Participants were encouraged to attend the recruiting clinic at days 1, 2, 3, 7, 14 and 28 after 
enrolment and at any time the child became ill. Field assistants visited the homes of children 
that failed to show up to collect additional samples. All staff engaged in the trial was blinded 
as to the treatment group of each child, apart from those administering medication.  
 
Microscopy and QT-NASBA  
Blood smears were stained for 10 minutes with 10% Giemsa and screened for asexual 
parasites and gametocytes at enrolment and on day 3, 7, 14 and 28 after treatment. Slides 
were declared negative if no parasites were observed in 100 microscopic fields, resulting in 
a sensitivity of roughly 5 gametocytes per µl. Asexual parasites and gametocytes were 
counted against 200 and 500 white blood cells, respectively. Densities were converted to 
parasites/µl by assuming a density of 8000 white blood cells per µl of blood. Parasite 
detection by QT-NASBA was done as described elsewhere [chapter 2, chapter 3]. Nucleic 
acids were extracted from 50µl blood samples as described by Boom et al. [61]. P. 
falciparum QT-NASBA was performed on a NucliSens EasyQ analyser (bioMérieux) as 
described elsewhere for Pfs25 mRNA [chapter 5]. The Pfs25 QT-NASBA is gametocyte 
specific and has a detection limit of 20-100 gametocytes/ml. Nuclisens Basic kits 
(bioMérieux) were used for amplification according to the manufacturers manual. A standard 
dilution series of in vitro cultured mature P. falciparum NF54 gametocytes [143] was included 
in each run. Parasite detection by QT-NASBA was done for a random selection of children 
from each treatment arm and for all the samples included in the membrane feeding assays. 
 
Mosquito membrane feeding and dissection  
Membrane feedings were conducted on day 14 after treatment, when gametocytes 
developing after treatment are expected to be mature [144]. Children were selected in two 
Chapter 8 
 76 
ways: (i) Children with microscopic gametocytaemia on day 7, which has been shown to be 
the peak prevalence after treatment [75, 145]. (ii) A random selection, regardless of 
microscopic gametocyte detection. Twenty-five children were selected for each treatment 
group. For all membrane feedings, venous blood samples of 3 ml were obtained from 
children older than 2 years and whose parent or guardian gave specific consent for the 
procedure. Each blood sample was fed to approximately 150 locally reared [128] 4 to 5-day-
old female Anopheles gambiae s.s. mosquitoes via an artificial membrane attached to a 
water-jacketed glass feeder maintained at 37ºC. After 10 to 15 minutes, fully fed mosquitoes 
were selected and kept at 27-29ºC for 7 days on glucose until midguts were dissected in 2% 
mercurochrome. The midguts were examined microscopically for oocysts with a second 
microscopist confirming their presence if observed. Experiments were considered valid if a 
minimum of 20 mosquitoes were dissected. For the randomly selected children, exactly 30 
mosquitoes were dissected per individual. 
 
Molecular genotyping 
For DNA analyses, blood was collected as dry blood on Whatman glass microfibre filter 
papers. DNA was extracted using a Chelex-based method. Alleles of the polymorphic locus 
msp2 were compared between pre- and post-treatment parasite isolates by PCR as 
previously described [78]. The procedure of Cattamanchi et al. [146] was followed, in that 
indeterminate samples in which a majority of novel bands appeared in the post-treatment 
infection were scored as new infections. 
 
Data analysis 
Therapeutic outcome was classified as early treatment failure (ETF), late treatment failure 
(LTF), reinfection or adequate clinical response (ACR) [149]. In case of treatment failure, 
rescue treatment was administered according to Kenyan national guidelines. Statistical 
analyses were carried out using SPSS for Windows, version 10 (SPSS Inc., Chicago, USA) 
and Stata 7.0 (Stata Corporation, Texas, USA). Proportions were compared using the chi-
squared statistic, the trend in proportions with the Cochran-Armitage trend test. Parasite 
densities were analysed after log-transformation. Normally distributed continuous variables 
were compared using ANOVA or Student t-test. Variables that were not normally distributed 
were compared using the Kruskal-Wallis test or Wilcoxon rank-sum test. For analyses on 
gametocyte prevalence during follow-up, multiple logistic regression models by Generalised 
Estimating Equations (GEE) were used to allow for auto-correlation. Regression coefficients 
(β) were calculated. Membrane feedings were analysed on two outcomes. The infectious 
proportion of the population was estimated by multiplying the proportion of selected children 
(by microscopy or randomly) with the proportion of these children that infected at least one 
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mosquito. In addition, the proportion of infected mosquitoes was determined in randomly 
selected children. Relative Risks (RR) with 95% confidence intervals (95% CI) were 
calculated with SP monotherapy as reference. 
 
RESULTS 
Clinical efficacy 
A total of 528 children were randomised over the four treatment arms (figure 8.1). Two 
children died within one day after enrolment, due the factors other than malaria. Of the 
remaining children 6.3% (33/526) was lost for evaluation during the 28-day follow-up period.  
Parasite density, gametocyte prevalence and fever prevalence at enrolment were not 
significantly different between the four treatment regimens (table 8.1). In CoArtem treated 
children, the median age (p=0.03), weight (p=0.03) and age-associated haemoglobin 
(p=0.01) were slightly higher because only children >10 kg were included in this group. 
During the 28-day follow-up, SP monotherapy gave adequate clinical response (ACR) in 
44% (63/143) and early treatment failure in 9.8% (14/143) of the children (table 8.2). The 
combination regimens resulted in fewer treatment failures and ACR was observed in 87.0% 
(100/115), 81.9% (131/160) and 96.0% (72/75) of the children treated with SP+AQ, SP+AS 
and CoArtem, respectively.  
 
 
 
Figure 8.1 Profile of the study 
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Table 8.1. Characteristics of the study population at enrolment 
 SP  SP+AS SP+AQ CoArtem 
N 152 174 127 75 
Age, median (IQR1) 3.5 (2.0 – 5.3) 3.1 (1.8-5.1) 2.6 (1.4-4.9) 4.1 (2.0-6.4) 
Sex2 50.7 49.4 52.8 53.3 
Weight, median (IQR1) 14.0 (11.0-18.4) 13.5 (10.0 – 18.0) 13.0 (10.0 – 16.1) 16.0 (12.0 - 20.2) 
Temperature3  66.2 (100/151) 64.7 (112/173) 53.5 (68/127) 54.7 (41/75) 
Haemoglobin, median 
(IQR1) 
9.4  
(7.9-10.7) 
9.4  
(7.8-10.6) 
9.3  
(8.0-10.7) 
10.4  
(8.6 – 11.8) 
Asexual parasite density,  
GM4 (IQR1) 
10122  
(3680 – 29593) 
12355 
 (5417 – 28521) 
11452 
 (5040 – 31679) 
11887  
(3680 – 32161) 
Gametocyte prevalence5 20.9 (31/148) 24.4 (42/172) 22.3 (27/121) 24.6 (17/69) 
1 IQR=interquartile range. 2 % male (n/N). 3 % fever (>37.5ºC) (n/N). 4 determined by microscopy GM= geometric 
mean. 5 % (n/N) by microscopy 
 
 
Table 8.2. Treatment outcome for the different treatment regimens on day 28. 
 SP  SP+AS SP+AQ CoArtem 
Day 28, number evaluated 143 160 115 75 
ACR 44.1 81.9 87.0 96.0 
ETF 9.8 0.6 0.9 0.0 
LTF 44.8 13.8 7.8 2.0 
Treatment outcome, % 
Re-infection 1.4 3.8 4.3 2.0 
ACR = adequate clinical response, ETF = early treatment failure, LTF = late treatment failure 
 
Gametocyte prevalence by microscopy and Pfs25 QT-NASBA  
Microscopic gametocyte prevalence during follow-up was significantly lower in SP+AQ, 
SP+AS and CoArtem treated children, compared to SP (figure 8.2A). Gametocyte 
prevalence by QT-NASBA was much higher than by microscopy (figure 8.2B). Overall 
gametocyte prevalence at enrolment was 22.9% (117/510) by microscopy, compared to 
89.4% (219/245) by QT-NASBA (χ2=295.9; p<0.001). Although gametocyte prevalence by 
Pfs25 QT-NASBA was almost universal at enrolment (85-92%), it decreased gradually 
during the follow-up period for SP+AQ (β=-0.060; se(β)=0.014, p<0.001), SP+AS (β=-0.090; 
se(β)=0.012, p<0.001) and CoArtem (β=-0.099; se (β)=0.015, p<0.001) but not for SP 
monotherapy (β=-0.0032; se(β)=0.15, p=0.83). 
During the entire study period, Pfs25 QT-NASBA gametocyte prevalence was lower in 
children treated with SP+AQ (p=0.001), SP+AS (p<0.001) and CoArtem (p<0.001) 
compared to those treated with SP. CoArtem treated children had the lowest Pfs25 QT-
NASBA prevalence of gametocytes although the difference with SP+AS was not statistically 
significant (p=0.27) (figure 8.2B).  
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A       B 
 
 
 
 
 
 
 
 
 
Figure 8.2. Gametocyte prevalence by microscopy for SP (closed diamonds), SP+AQ (open triangles), SP+AS 
(open squares) and CoArtem (closed triangles). Bars indicate the 95% confidence intervals around the 
proportions. A. Microscopy. Differences in gametocyte prevalence were statistically significant for the comparison 
between SP and SP+AS (β=-0.78, se(β)=0.17, p<0.001) and CoArtem (β=-1.14, se(β)=0.26, p<0.001); between 
SP+AQ and SP+AS (β=-0.70, se(β)=0.19, p<0.001) and CoArtem (β=-1.06, se(β)=0.27, p<0.01). Differences in 
gametocyte prevalence were not significant for the comparison between SP and SP+AQ (β=-0.08, se(β)=0.18, 
p=0.67) and between SP+AS and CoArtem (β=-0.35, se(β)=0.27, p=0.18).   
B. Pfs25 QT-NASBA. Differences in gametocyte prevalence were statistically significant for the comparison 
between SP and SP+AQ (β=-1.31, se(β)=0.38, p=0.001); SP+AS (β=-2.14, se(β)=0.33, p<0.001) and CoArtem 
(β=-2.44, se(β)=0.37, p<0.001); between SP+AQ and SP+AS (β=-0.83, se(β)=0.30, p=0.007) and CoArtem (β=-
1.12, se(β)=0.34, p=0.001). There was no significant difference in gametocyte prevalence between SP+AS and 
CoArtem (β=-0.30, se(β)=0.27, p=0.27). 
 
Infectiousness of children in different treatment arms 
A total of 118 successful membrane feedings were carried out in children who had 
microscopically detectable gametocytes on day 7 after enrolment. A high proportion of these 
gametocyte carriers was infectious to mosquitoes (table 8.3A). The estimated infectious 
proportion of the population was significantly lower after treatment with SP+AS (RR 0.30, 
95% CI 0.20-0.46) and CoArtem (RR 0.30, 95% CI 0.17-0.53) when compared with SP 
monotherapy. No statistically significant difference was observed between SP and SP+AQ. 
However, the high gametocyte prevalence in the Pfs25 QT-NASBA prompted us to randomly 
test blood samples from treated children in the membrane feedings. The proportion of 
randomly selected children that was infectious to mosquitoes (table 8.3B) was consistently 
higher than the estimated proportion based on microscopically confirmed gametocyte 
carriers (table 8.3A). This was observed for SP monotherapy (64.0% compared to 48.4%), 
although the relative increase was most evident for combination therapy, where the 
infectious proportion increased threefold for SP+AS (44.0% compared to 14.7%), twofold for 
SP+AQ (80.0% compared to 37.9%) and fourfold for CoArtem (60% compared to 14.0%). 
Compared to SP monotherapy, there was no statistically significant reduction in the 
infectious proportion of the population for SP+AS (RR 0.69, 95% CI 0.40-1.17) SP+AQ (RR 
1.25, 95% CI 0.88-1.78) or CoArtem (RR 0.94, 95% CI 0.61-1.45) treated children (table 
8.3B). 
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Table 8.3. The estimated proportion of infectious children at day 14 after treatment per treatment arm in (A) 
children microscopically confirmed gametocyte positive at day 7 and (B) a random selection of patients. 
A. Microscopically confirmed gametocyte carriers  
 Gametocytaemic 
children1,2 
Infection in the 
membrane feedings1
Proportion infectious 
children, %* RR (95% CI)†
SP 61.5 (83/135) 78.7 (48/61) 48.4 1
SP+AS 23.8 (39/164) 61.9 (13/21) 14.7 0.30 (0.20 – 0.46)
SP+AQ 46.2 (55/119) 82.1 (23/28) 37.9 0.79 (0.59 – 1.05)
CoArtem 16.0 (12/  75) 87.5 (  7/  8) 14.0 0.30 (0.17 – 0.53)
B. Random selection of patients  
 
 
Proportion infectious 
children, %*,1 RR (95% CI)†
SP  64.0 (16/25) 1
SP+AS  44.0 (11/25) 0.69 (0.40 – 1.17)
SP+AQ  80.0 (20/25) 1.25 (0.88 – 1.78)
CoArtem  60.0 (15/25) 0.94 (0.61 – 1.45)
1 percentage (n/N). 2 determined by microscopy. RR=relative risk; 95% CI = 95% confidence interval. The median 
number of dissected mosquitoes per experiment was 31.0 (IQR 30-48) for table 8.3A and not different between 
the treatment groups (Kruskal-Wallis χ2 =0.88; p=0.83). The number of dissected mosquitoes for table 8.3B was 
exactly 30 for each experiment. *The proportion of infectious children was estimated for table 8.3A by multiplying 
the gametocytaemic proportion of children with the proportion of children that infected at least one mosquito in 
the membrane feedings. For table 8.3B this was determined directly. †The relative risk for the infectious 
proportion of the population with SP as reference group. 
 
The force of malaria infection in the natural situation is determined by the infectious 
mosquito reservoir. The infectious mosquito reservoir is related to the infectious proportion of 
the human population but also to the average number of infected mosquitoes when feeding 
on humans. This was quantified as the probability of mosquito infection, which was 4.8% 
after feeding on SP treated children and was significantly reduced after treatment with 
SP+AS (RR 0.15, 95% CI 0.10-0.23), SP+AQ (RR 0.38, 95% CI 0.27-0.53) and CoArtem 
(RR 0.18, 95% CI 0.11-0.29) (table 8.4A). The probability of mosquito infection was 
considerably higher when based on the random selection of children (table 8.4B), compared 
to microscopic gametocyte carriers (table 8.4A). When based on random feeds, the 
probability of mosquito infection was 1.4 times higher for SP (6.9% compared to 4.8%), 3.3-
fold higher for SP+AS (2.3 compared to 0.7%), 3.1-fold higher for SP+AQ (5.5% compared 
to 1.8%) and 4.5-fold higher for CoArtem treated children (3.6% compared to 0.8%). 
Compared to SP monotherapy, the probability of mosquito infection in randomly selected 
children was significantly lower for SP+AS (RR 0.33, 95% CI 0.19 – 0.56) and CoArtem 
treated children (RR=0.52, 95% CI 0.33- 0.82). There was no difference between SP and 
SP+AQ in the probability of mosquito infection.  
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Table 8.4. The probability of mosquito infection in the membrane feedings at day 14 after treatment in (A) 
children microscopically confirmed gametocyte positive at day 7 and (B) a random selection of patients. 
A. Microscopically confirmed gametocyte carriers  
 Gametocytaemic 
children1,2 Infected mosquitoes1
Probability of mosquito 
infection, %* RR (95% CI)†
SP 61.5 (83/135) 7.8 (186/2382) 4.8 1
SP+AS 23.8 (39/164) 3.1 (  23/  754) 0.7 0.15 (0.10 – 0.23)
SP+AQ 46.2 (55/119) 3.9 (  42/1072) 1.8 0.38 (0.27 – 0.53)
CoArtem 16.0 (12/  75) 5.3 (  18/  340) 0.8 0.18 (0.11 – 0.29)
B. Random selection of patients  
 
 
Probability of mosquito 
infection, %*,1 RR (95% CI)†
SP  6.9 (52/750) 1
SP+AS  2.3 (17/750) 0.33 (0.19 – 0.56)
SP+AQ  5.5 (41/750) 0.79 (0.53 – 1.17)
CoArtem   3.6 (27/750) 0.52 (0.33 – 0.82)
1 percentage (n/N). 2 determined by microscopy. *The probability of mosquito infection was estimated for table 
8.4A by multiplying the proportion of gametocytaemic children with the proportion of infected mosquitoes. For 
table 8.4B this was determined directly. †The relative risk for the probability of mosquito infection (4th column) with 
SP as reference group. 
 
DISCUSSION 
This study shows that the influence of ACT on the infectiousness of young children to 
mosquitoes is moderate in a high endemic area in Kenya. Although ACT reduces 
gametocyte densities [chapter 5] and the proportion of infected mosquitoes, submicroscopic 
gametocyte densities are sufficient to drive post-treatment malaria transmission. When 
including submicroscopic gametocytaemia, the proportion of infectious children 14 days after 
treatment is similar in all tested drug regimens. Our conclusions contradict other studies that 
show strong effects of ACT on post-treatment malaria transmission [75, 78, 138]. Our 
microscopic findings on post-treatment gametocyte prevalence are similar to other studies 
on SP [75, 145], SP+AS [75, 76, 145, 148], SP+AQ [137, 145, 148] and CoArtem [78, 137]. 
The infectiousness of gametocyte carriers is was somewhat higher in our study [75, 78], 
possibly as a result of the different days of membrane feedings. We conducted the 
experiments on day 14 after treatment, compared to day 7 in previous studies [75, 78] when 
gametocytes may not be fully mature [144] or less infectious due to residual drug 
concentrations [32]. We nevertheless consider this possibility unimportant for interpreting our 
data since our findings on infectiousness based on microscopy are comparable and lead to 
the same conclusions. With microscopy data, we observe a clear reduction in malaria 
transmission after treatment with ACT, i.e. treatment with SP+AS [75] or CoArtem [78]. No 
estimate was previously given for SP+AQ, which appears to be similar to SP monotherapy in 
terms of post-treatment transmission potential. The results of membrane feedings in 
randomly selected children, however, lead to very different conclusions. The most likely 
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explanation for this is that microscopic detection of gametocytes only represents the tip of 
the iceberg. Random feeding experiments convincingly show that relying on microscopic 
selection of gametocyte carriers leads to an overestimation of the effect of drugs on malaria 
transmission. This is evident for all tested treatment regimens and attributable to 
submicroscopic gametocytaemia. The true proportion of gametocyte carriers in children 
presenting with clinical malaria is up to four times higher when based on the Pfs25 QT-
NASBA. This proportion decreases markedly after ACT treatment, suggesting a direct effect 
of artemisinin derivatives on gametocyte survival [78, 149]. In contrast to SP, ACT seems to 
limit the period of infectiousness. Despite the evident reduction in gametocytaemia following 
ACT, the majority of children harbour gametocytes at or below the microscopic detection 
limit during the first two weeks after treatment. A large proportion of these submicroscopic 
gametocyte carriers is capable of infecting mosquitoes. Infectiousness below the 
microscopic threshold is not unexpected [64, 87, 92], but the relative contribution of 
individuals with submicroscopic gametocytaemia to post-treatment malaria transmission is 
remarkable. While a recent study concludes that CoArtem is highly effective in preventing 
post-treatment malaria transmission [78], we find that 60% of the children treated with 
CoArtem is capable of infecting mosquitoes. Our study shows that ACT does not 
substantially reduce the proportion of infectious children but results in a significantly lower 
proportion of infected mosquitoes. In this manner, ACT may have beneficial effects on 
transmission compared to SP. 
Considering our findings on post-treatment transmission, the previously reported reduction in 
the spread of resistant parasite strains [27, 80, 139], potentially one of the most important 
effects of ACT, will need to be re-assessed using sensitive gametocyte detection techniques 
or random feeding experiments. Subpatent gametocytaemia is a relevant factor in 
mathematical models on general malaria transmission [24] and the development and spread 
of parasite resistance [150]. Parasite resistance to SP is common in our study area, with 
more than half of the children experiencing treatment failure during follow-up. This 
observation is similar to recent studies from Kenya and Uganda [148, 151, 152]. The efficacy 
of SP combination therapy is high, as previously reported for SP+AQ [148, 153] and SP+AS 
[148]. CoArtem gives the best clinical response with only 2% treatment failure, which is 
identical to recent findings from Uganda and Tanzania [137, 154].  
Transmission intensity varies significantly in Africa and is determined by the mosquito 
reservoir and gametocyte prevalences in the population. We dissected thirty fully fed 
mosquitoes per individual patient, which reflects approximately one-week exposure to 
mosquito bites in our study area [155]. Considering an individual’s infectious period, this 
makes our estimates reasonable for the local situation but results clearly need to be 
interpreted in the context of biting rates for other endemicities. In our area the gametocyte 
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prevalence at enrolment was roughly 90%. During a previous study on malaria transmission 
after CoArtem treatment in the Gambia [78], where transmission intensity is much lower, a 
number of children without microscopically detectable gametocytes before or after treatment 
were included in membrane feeding experiments. Only 3.2% (1/31) of these experiments 
resulted in mosquito infection (Sutherland et al.., unpublished data), which is much lower 
than our findings. This suggests that submicroscopic gametocyte densities may be less 
common in the Gambia. In contrast, findings from a low endemic are in Sudan suggest a 
high prevalence of 12-45% submicroscopic gametocytaemia in the general population [66]. 
Future studies in areas of different transmission intensity should determine the relation 
between transmission intensity and submicroscopic gametocyte prevalence. 
In conclusion, our findings need to be interpreted in the context of transmission intensity but 
stress that none of the tested drug combinations can clear all children from gametocytes in 
the month following treatment. ACTs in general, and CoArtem in particular, are efficacious 
as treatments of uncomplicated malaria and able to limit the period of post-treatment 
gametocyte carriage. However, due to the contribution of submicroscopic gametocyte 
densities, infectiousness appears to be rule rather than exception after treatment. These 
findings are sobering for interventions aiming to reduce transmission by the use of 
antimalarial drugs and indicate that gametocyte detection by microscopy is insufficient for 
future studies on malaria transmission.  
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INTRODUCTION 
The work described in this thesis, is primarily based on development of a new assay that 
makes quantitative gametocyte research more feasible. The Pfs25 mRNA QT-NASBA for 
quantification of gametocytes has a quantification limit of 20-100 gametocytes/ml blood 
when using real-time detection and 50µl blood samples. Quantification is significantly 
correlated to microscopical quantification and control samples from in vitro culture, malaria-
free Dutch and Kenyan blood donors as well as P. falciparum infected Dutch volunteers 
confirmed specificity of this assay for gametocytes. Some technical considerations on the 
Pfs25 QT-NASBA are discussed in the first part of this chapter. The research results are 
discussed and placed into a context of malaria control in the second part and some final 
questions are discussed in part 3. 
 
TECHNICAL CONSIDERATIONS 
Pfs25 QT-NASBA – is it female specific? 
The QT-NASBA, developed for quantification of mature gametocytes [chapters 2 and 5], is 
based on quantification of Pfs25 mRNA that is also used for sensitive detection of 
gametocytes by reverse-transcriptase PCR [39, 65, 66]. The Pfs25 gene encodes a 25kD 
membrane protein that is not present on the surface of gametocytes, but expressed at the 
surface upon gametogenesis and during the parasite stages developing in the mosquito 
midgut [10, 156-159]. The function of the protein is not yet known, but data from the 
orthologous P25 gene in the rodent malaria parasite Plasmodium berghei indicate that, 
although redundant, the P25 gene in P. berghei may be involved in ookinete/oocyst 
development in the mosquito [160]. Whether the same is true in P. falciparum remains to be 
investigated. 
Pfs25 protein expression is preceded by mRNA expression in late stage gametocytes [161]. 
Transcription can be detected as early as 32-52 hrs after red blood cell invasion [20], it is 
reported to be low in gametocytes, increasing after the onset of gametogenesis and mRNA 
is still present in zygotes [59, 158, 161]. Activation of the promoter may partially rely on DNA 
binding proteins [60] and P25 protein expression is most likely regulated post-
transcriptionally [162]. 
Data from studies of the P25 gene in P. berghei indicate that both the mRNA and the protein 
may be expressed only in female parasites (J.A.M. Braks and C.J. Janse, LUMC Leiden, 
unpublished data). With the P25 gene in P. falciparum showing quite some similarities to the 
P25 gene in P. berghei we cannot yet exclude the possibility that Pfs25 mRNA is expressed 
only in female gametocytes. This may imply that only part of the gametocyte population can 
be detected. However, it may not influence our results to a large extent because of the 
following reasons: 
Chapter 9 
 87
1) We have observed very little variation in quantification by QT-NASBA in comparison to 
microscopy of gametocytes from our in vitro culture of strain NF54, nor in several other 
strains that were tested. Possible sources of variation from biological differences 
between samples, RNA extraction and QT-NASBA were included in the calculations of 
interassay variability. This variability was 4-10% for all tested concentrations of 
gametocytes with a variability of below 10% considered appropriate for biological assays. 
This indicates either that the sex ratios of gametocytes from our culture are relatively 
stable both within and between the strains tested and/or that Pfs25 mRNA is expressed 
in both sexes. 
2) In general, Plasmodium parasites have a female-biased sex ratio, indicating that the 
possibility of not counting the male gametocytes in the population would be a relatively 
small error in the total quantification. Additionally, gametocyte densities in the test 
samples are calculated with the use of a gametocyte control series from in vitro culture. 
This means that only when sex ratios between the tested field samples and control 
samples are very different this may cause an underestimate or overestimate of 
gametocyte density. Calculations, including possible variations in sex ratios between 3 
and 10 females for each male gametocyte [6, 21, 64, 111, 143, 163-167] for both field 
samples and controls from in vitro culture, suggest that deviations from the real 
gametocyte density, caused by detection of only female gametocytes, would be  
a) overestimates when the field samples, but not the control samples, are highly female-
biased. In that case, gametocyte densities may be overestimated up to a two-fold 
difference in extreme cases of sex ratios.  
b) underestimates when the control samples, but not the field samples, are highly 
female-biased. In this case, gametocyte densities may be underestimated up to a two-
fold difference. 
Laboratory experiments have shown that our gametocyte culture in general shows a 
relatively low female bias, with 3-4 female gametocytes per male gametocyte, thus 
decreasing the risk of underestimating gametocyte densities in case Pfs25 would be 
female-specific. This still leaves the option of overestimating gametocyte densities if the 
field samples would be highly female-biased. Sex ratios were determined in some of the 
collected field samples and we have not observed highly female-biased sex ratios. In 
general sex ratios varied from 2-5 females per male gametocyte, which is not an 
uncommon observation in the field [64, 163, 168]. The observed sex ratios in the field 
and in the laboratory would result in less than a 1.2-fold deviation from the real number 
of gametocytes in case Pfs25 mRNA expression would be female-specific. 
Little effort was made to determine the sex ratios in all samples and we cannot yet confirm 
female-specificity of Pfs25 mRNA expression in gametocytes. Therefore we cannot exclude 
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the possibility that gametocyte counts in individual field samples with extreme sex ratios may 
result in a slightly inaccurate quantification. However, deviations from the real number of 
gametocytes seem to be limited to a maximum of a two-fold difference and even lower if sex 
ratios are not extremely biased. Taking this into account and with research outcomes based 
upon gametocyte densities in population groups, we conclude that the possibility of female-
specific Pfs25 mRNA expression would not considerably change the overall results of our 
study. To determine possible female-specific expression of Pfs25 mRNA in P. falciparum 
gametocytes, we are planning in situ hybridisation assays using antisense RNA probes in 
the near future. 
 
Gametocyte quantification by QT-NASBA or microscopy – what are the real numbers? 
In all tested samples, we find a significant correlation between microscopical counts and 
Pfs25 QT-NASBA quantification of gametocytes. Correlation in samples from in vitro culture 
are much better than those from in vivo samples, most likely because approximate 
quantification of low density samples from serial dilutions could be included in the 
calculations. In the in vivo samples, densities below the microscopical detection limit were 
scored as zero in microscopy but as positive in QT-NASBA. Submicroscopic levels of 
gametocytes were present in 65% of the samples in the Kenyan study and in 64% in Burkina 
Faso, suggesting a large influence of submicroscopic samples in the calculation of 
correlation between QT-NASBA and microscopy. Such samples are consistently not 
detected by microscopy. 
However, a clear difference was seen in quantification of gametocytes from samples of 
microscopically confirmed gametocyte carriers. In those samples, QT-NASBA in general 
resulted in a lower quantification than microscopy. This difference was consistently seen in 
the in vivo samples and was in the order of magnitude of a 0.6-0.7 10log difference in median 
gametocyte density in both in Kenya and Burkina Faso. This seems to result mostly from 
differences in the lower densities where NASBA can even result in gametocyte 
concentrations 20-30 times lower than determined by microscopy. In the lower 
concentrations, QT-NASBA can still vary in concentrations while the lowest quantification by 
microscopy is always confined to 1.60*104 because gametocytes are counted against 500 
leucocytes. However, 100 fields were screened before declaring a sample negative and 
counting of gametocytes against 500 leucocytes was started only after the first gametocyte 
had been detected, which introduces a positive bias in quantification. Every positive sample 
will contain at least 1 gametocyte/500 leucocytes (=1.60*104/ml), irrespective of how many 
fields had been observed before finding the first gametocyte and starting the count. When 
including the number of fields observed before the first gametocyte was detected, this could 
cause approximately a 4-fold quantification difference between seeing a gametocyte in the 
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1st and the 100th field. The effect may be smaller than this factor because samples with 
gametocytes observed in the first field are more likely to contain higher densities of 
gametocytes and may therefore be more accurately counted by microscopy. When taking 
into account the smaller absolute volume investigated by microscopy (0.06 µl) compared to 
by QT-NASBA (2.5 µl), a single parasite detected by both assays would result in an 
approximate 40-fold overestimate of gametocyte density by microscopy. When many fields 
were observed before detecting the first gametocyte by microscopy, this difference will be up 
to 4 times smaller. A 20-30 times lower quantification by QT-NASBA in the lower densities of 
microscopically-confirmed gametocytes is therefore not very surprising. 
Possible other causes of lower quantification by QT-NASBA may include the detection of 
non-viable gametocytes by microscopy or a higher quality and RNA expression level in 
gametocytes from in vitro culture, used as quantitative control for QT-NASBA, compared to 
in vivo gametocytes. The above-discussed possibility of Pfs25 female-specific mRNA 
expression is not considered a possible cause; field samples are generally more female-
biased than control samples from in vitro culture, typically resulting in the risk to 
overestimate, not underestimate, gametocyte numbers by QT-NASBA. 
Although we cannot unambiguously determine which technique represents the ‘real’ number 
of gametocytes, the data suggest that, if gametocytes are microscopically detected, 
microscopy may overestimate gametocyte counts, especially at the lower gametocyte 
densities. We therefore expect that the differences in quantification by NASBA and 
microscopy are the result of a technological bias causing overestimation of gametocyte 
numbers by microscopy. The overall differences in quantification represent only 3-4% of all 
samples [chapters 5 and 6] and can be considered negligible in the overall interpretation of 
the results. 
 
Multiplex QT-NASBA: is it feasible? 
The prospective development of multiplex QT-NASBA, i.e. the detection of multiple targets 
within one reaction, for detection of various P. falciparum developmental stages would 
increase the value of QT-NASBA for malaria studies and would considerably decrease costs 
of analysis. With the real-time QT-NASBA for quantification of the total P. falciparum parasite 
load (18S rRNA) and gametocytes (Pfs25 mRNA) performed at the same potassium chloride 
concentration, we expected that the combination of both assays into a multiplex assays 
would not be too difficult. A preliminary test for multiplexing using electrochemiluminescence 
endpoint detection seemed promising (figure 9.1) but was performed only once because the 
18S and Pfs25 NASBA assays were already adapted into real-time assays. 
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However, several experiments (data not shown) showed that the theoretical possibility of a 
multiplex for QT-NASBA was quite a bit more complicated for quantitative real-time 
detection. Results for 18S rRNA and Pfs25 mRNA real-time QT-NASBA were compared 
between monoplex and multiplex assays. It seems that results of Pfs25 real-time NASBA are 
similar in monoplex and multiplex and thus not affected by the presence of 18S amplification 
in the same tube. However, 18S amplification and detection is less efficient when performed 
in multiplex compared to monoplex. Experiments were performed to identify which of the 
components of the multiplex QT-NASBA reaction might be the cause of inhibition of 18S 
amplification. Inhibition depended on enzyme concentrations and most likely resulted from a 
limiting amount of enzymes in the multiplex reaction due to the additional amplification of 
Pfs25. Such an effect may not be observed for Pfs25 in the multiplex as the amount of Pfs25 
mRNA present in each sample is much lower compared to that of 18S rRNA and the relative 
inhibition would be more difficult to observe. This problem was avoided by increasing the 
enzyme concentration but unfortunately this only partly resolved the inhibition. Further 
experiments showed that the inhibition resulted from a complex interaction between 
reagents in the multiplex reaction that affects only amplification of the 18S target. As the 
inhibition was not observed in the preliminary multiplex experiment using 
electrochemiluminescence endpoint detection, we conclude that interactions with the 
molecular beacon for Pfs25 real-time detection, present at a higher concentration than the 
18S molecular beacon, may be involved in the inhibition of 18S amplification. As the 
optimisation of multiplex QT-NASBA for quantification of malaria parasites proved difficult 
and software for quantitative multiplex NASBA is not yet available, it seems not feasible at 
this moment to develop multiplex malaria NASBA for quantitative high throughput analyses.  
 
Figure 9.1.  Multiplex for 18S
rRNA QT-NASBA and Pfs25
mRNA QT-NASBA using
electrochemiluminescence 
endpoint detection 
Open triangles: 18S monoplex 
Closed triangles: 18S multiplex 
Open circles: Pfs25 monoplex 
Closed circles: Pfs25 multiplex 
The outlier for 18S monoplex was
probably a mistake in pipetting 
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RESULTS IN THE CONTEXT OF TRANSMISSION AND CONTROL 
Results from the drug efficacy study in Mbita, Kenya [chapter 8] as well as other studies in 
Kenya and Uganda [148, 151, 152] showed that drug resistance to SP is high and a change 
of drug treatment policies in this area is urgently needed. The tested alternative combination 
treatment regimens had a better efficacy compared to SP with adequate clinical response in 
82%, 87% and 96% for SP+AS, SP+AQ and CoArtem respectively, which is similar to other 
reports from Kenya and Uganda [137, 148, 153, 154]. The increased costs for treatment with 
artemisinin-based combination therapies (ACT) may be justified by these better cure rates in 
combination with the alleged gametocytocidal effects of artemisinin derivatives. A strong 
effect of ACT on post-treatment malaria transmission was shown in [75, 78, 138] and our 
study confirmed the reduction of gametocytes after ACT [chapters 5 and 8]. 
Our data show that the gametocyte reservoir in the study areas, as detected by Pfs25 QT-
NASBA, was 3 to 4-fold higher than previously indicated by microscopical analyses 
[chapters 5, 6 and 8]. Submicroscopic levels of gametocytes were very common as was 
previously reported from studies in Sudan [66, 87] and are considered of epidemiological 
importance [chapter 7]. A large proportion of submicroscopic gametocyte carriers are 
capable of infecting mosquitoes, some even at densities below the threshold of the Pfs25 
QT-NASBA. This is not unexpected [64, 86, 92, 116, 118, 120, 123, 124], but the relative 
contribution of low-density gametocyte carriers to post-treatment malaria transmission is 
remarkable. The proportion of children selected for microscopically confirmed gametocytes 
that could infect mosquitoes was similar to that of children with submicroscopic 
gametocytaemia, but the latter group infected fewer mosquitoes. When including 
submicroscopic gametocyte carriers, infectiousness was rule rather than exception. The 
proportion of infectious children was similar for all tested treatment regimens although fewer 
mosquitoes were infected after ACT, which may still reduce transmission. Our data suggest 
that the potential of malaria transmission remains high even after treatment with ACT.  
 
Submicroscopic gametocytaemias are present in large numbers of individuals, both in 
symptomatic and asymptomatic individuals, in all age groups and possibly over prolonged 
periods. Based on microscopy data, it is often assumed that the infectious reservoir is mainly 
in (symptomatic) children [86, 100, 105] even though contradicting results have been 
published on this matter [64, 101, 103, 104]. As a result, intervention strategies are designed 
with main focus on the youngest age groups. However, our results indicate that all age 
groups as well as asymptomatic carriers may contribute to the infectious reservoir, and 
although their levels of contribution may vary with the distribution of various age groups in 
the population, control of transmission may only be possible if targeted at the entire 
population. 
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The results presented in this thesis were obtained from controlled studies at a certain place 
and time in a defined population group. Although confirmation of high levels of 
submicroscopic gametocytes were obtained from both Kenya and Burkina Faso and 
supported by previous suggestions for their existence in other parts of the world [66, 92]; one 
should be careful with generalization of the conclusions of this study. Similar studies in other 
geographical areas, with different epidemiological settings, vectors, disease patterns, 
demography and control strategies do not necessarily result in the same observations. It is 
important to interpret our results on post-treatment transmission in the context of natural 
transmission conditions. During the study in Kenya, we dissected 30 fully fed mosquitoes per 
individual patient, which reflects approximately one-week exposure to mosquito bites in our 
study area. Considering an individual’s infectious period, this makes our estimates 
reasonable for the local situation but results clearly need to be interpreted in the context of 
endemicity for other sites. 
 
With these results, we may have to change our view on the transmission potential of malaria 
parasites, with subsequent implications for malaria control. We would like to emphasize that 
accurate estimates of the infectious reservoir are very important and should be included in 
intervention programs. The potential contribution of submicroscopic gametocyte carriers to 
the infectious reservoir should not be underestimated. The large numbers of individuals with 
submicroscopic gametocytaemias could counterbalance the observation that they may infect 
fewer mosquitoes, with considerable effects on overall estimates of the infectious reservoir 
and probability of mosquito infection [chapter 8]. Inclusion of accurate data on gametocyte 
prevalence and density, in combination with transmission studies on the infectivity of these 
gametocytes, should allow a better targeting of control efforts as well as more realistic 
estimates of the effects expected from such interventions.  
 
FURTHER QUESTIONS 
How is gametocyte development regulated? 
The results from follow-up of primary, experimental human infections, presented in chapter 
2, show that sexual commitment occurs very early during a primary infection, probably 
already in the parasites that are released from the liver. However, these parasites, 
committed to sexual development, do not seem to successfully complete development into 
mature gametocytes. One possible explanation for this is that sexual stage maturation is 
regulated by some mechanism after commitment to the sexual pathway (expression of Pfs16 
mRNA), and before expression of Pfs25 mRNA. 
If commitment to the sexual pathway of development occurs this early in an infection, we 
may expect a relation between the level of sexual commitment and asexual parasite density, 
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especially in the absence of previous exposure and acquired immunity. We have not been 
able to confirm such a quantitative relation statistically, but Pfs16 mRNA levels tend to follow 
the pattern of asexual development. The lack of a direct quantitative relation between the 
level of Pfs16 mRNA and asexual parasitaemia may partly be the result of mRNA levels 
below the detection limit of Pfs16 QT-NASBA. Additionally, the rapid disappearance Pfs16 
mRNA from the circulation within one proliferation cycle indicates that a variable amount of 
sexually committed parasites is present in the circulation and suggests some influence of 
sequestration of sexually committed parasites. 
Although we have gathered some more information regarding the development of early 
sexual stages in P. falciparum, we cannot yet elucidate the process that regulates sexual 
stage development. With the development of QT-NASBA for quantification of P. falciparum 
at various stages of development it may be possible to study the process of sexual stage 
development in more detail. 
 
Why is it so difficult to control transmission? 
The usually low prevalence and densities of gametocytes in infected persons hamper 
studies using standard microscopy and it remains a question why it is so difficult to control 
transmission of P. falciparum malaria considering the relatively small numbers of 
gametocytes detected by microscopy. However, the use of QT-NASBA showed that there 
are not that little gametocytes: when including submicroscopic levels, most carriers of 
Plasmodium falciparum as well as quite some people who do not have symptoms or asexual 
parasites seem to carry gametocytes and may therefore transmit malaria. This result is yet to 
be confirmed in other epidemiological settings, but should be included in the design of 
methods for intervention and control of malaria disease and transmission. Control programs 
have mostly been limited to microscopical detection of gametocytes, and the possible effects 
that could be obtained by various intervention methods targeting transmission may have 
been overestimated. 
Although unfortunately our results may indicate that Plasmodium falciparum transmission 
may be much more prevalent than previously thought and is possibly more difficult to control, 
more accurate knowledge about the infectious reservoir, the efficiency of transmission and 
distribution of risk may allow a better targeting of control efforts and should get us one step 
closer to answering the question above. 
 
  
  95
Summary 
The malaria parasite Plasmodium falciparum can be transmitted from man to mosquito when 
a mosquito ingests the sexual parasite stages (gametocytes) during blood feeding. It seems 
as if these gametocytes occur in relatively small numbers, but malaria is transmitted 
efficiently. To investigate this interesting subject, a sensitive, accurate and quick method to 
quantify P. falciparum parasites and specifically gametocytes was needed. Microscopy was 
not sensitive enough for this purpose. The development of a quantitative molecular 
technique (QT-NASBA), based on amplification of genetic material (RNA) of 1) P. falciparum 
parasites, 2) young sexual parasites and 3) mature gametocytes, is described in chapter 2. 
These QT-NASBAs were used to study the dynamics of parasites and gametocytes in 
volunteers with experimental P. falciparum infections. It was demonstrated that parasites 
start sexual development very early during infection but without subsequent maturation into 
mature gametocytes [chapter 2]. 
QT-NASBA for quantification of P. falciparum was improved with modern detection 
technology allowing detection of RNA levels during amplification (real-time) instead of 
endpoint detection. Real-time QT-NASBA was evaluated and compared to a real-time assay 
based on amplification of DNA (PCR) that was routinely used in our laboratory. Both 
techniques were comparable in sensitivity and specificity, but QT-NASBA results were 
obtained in a shorter time-span and with use of smaller blood samples. Therefore, QT-
NASBA is considered more practical than real-time PCR for the quantification of P. 
falciparum parasites [chapter 3]. 
Facilities to store samples at –70ºC are often limited during field research. An adapted 
protocol for storage of samples at -20ºC was evaluated to facilitate the collection of field 
samples for QT-NASBA, [chapter 4]. This storage protocol was used during subsequent 
studies in Kenya and Burkina Faso and proved successful.  
Application of real-time technology to QT-NASBA for quantification of mature gametocytes is 
described in chapter 5. In this chapter, gametocytes were studied in Kenyan children with 
uncomplicated, symptomatic P. falciparum infections, during and after treatment with 
antimalarial drugs. QT-NASBA showed that many children harboured gametocytes, both 
before and after treatment with sulphadoxine-pyrimethamine (SP) or SP+artesunate. 
Frequently, children harboured gametocytes at densities below the microscopical detection 
limit. Although artesunate combination therapy resulted in significantly lower prevalence and 
density of gametocytes compared to SP monotherapy, not all gametocytes were eliminated. 
These results indicate that previous estimates of the gametocyte reservoir in the human 
population were probably underestimates. 
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In chapter 6, the frequent presence of submicroscopic gametocytaemia was confirmed in 
individuals of all ages with asymptomatic P. falciparum in Burkina Faso. The data showed 
that gametocytes are less prevalent with increasing age. This may depend on the age-
related decrease of asexual parasites. 
Whether submicroscopical levels of gametocytes are of epidemiological importance was 
investigated in the laboratory by feeding dilution series of P. falciparum gametocytes to 
Anopheles stephensi mosquitoes and monitoring subsequent mosquito infection. The 
probability of mosquito infection increases with the number of gametocytes present in the 
blood. However, very low densities of gametocytes can still infect mosquitoes and are 
therefore of epidemiological importance. This was confirmed by field studies in Kenya 
[chapter 7]. 
The previous chapters emphasise the importance of submicroscopical levels of 
gametocytes. In chapter 8, the effect of drug treatment on malaria transmission is described. 
Three drug treatment regimens that are considered for replacement of SP in Kenya, were 
tested for clinical efficacy and their effect on transmission to Anopheles gambiae 
mosquitoes. All three tested regimens had a higher clinical efficacy than SP. Additionally, a 
reduction of gametocytes was observed after artemisinin combination therapy. This did not 
decrease the proportion of children capable of infecting mosquitoes but it did decrease the 
proportion of infected mosquitoes. The results presented in this thesis are discussed in 
chapter 9. 
 
  97
Samenvatting 
De malariaparasiet Plasmodium falciparum kan van mens naar mug worden overgedragen 
als de seksuele stadia van de parasiet (gametocyten) tijdens het nemen van een 
bloedmaaltijd door een mug worden opgezogen. Deze gametocyten lijken relatief weinig 
voor te komen, hoewel de transmissie van malaria efficiënt verloopt. Om dit interessante 
gegeven nader te onderzoeken was een gevoelige, nauwkeurige en snelle methode nodig 
om P. falciparum parasieten en vooral gametocyten te kwantificeren. Microscopie was 
daarvoor niet gevoelig genoeg en de ontwikkeling van een kwantitatieve moleculaire 
techniek (QT-NASBA), gebaseerd op het vermenigvuldigen van genetisch materiaal (RNA) 
van 1) P. falciparum parasieten, 2) jonge seksuele parasieten en 3) volgroeide gametocyten, 
is beschreven in hoofdstuk 2. Deze QT-NASBAs werden gebruikt om de dynamiek van 
parasieten en gametocyten te bestuderen in vrijwilligers met experimentele P. falciparum 
infecties. Hierbij werd aangetoond dat parasieten al erg vroeg in een infectie beginnen aan 
seksuele ontwikkeling maar zonder volgroeiing tot volwassen gametocyten [hoofdstuk 2]. 
QT-NASBA voor het kwantificeren van P. falciparum werd verbeterd met behulp van 
moderne detectietechnieken waardoor de hoeveelheid RNA tijdens de vermenigvuldiging 
(real-time) wordt gemeten in plaats van de eindopbrengst. Real-time QT-NASBA werd 
geëvalueerd en vergeleken met een real-time test gebaseerd op vermenigvuldiging van DNA 
(PCR) die in ons laboratorium routinematig werd gebruikt. Beide technieken bleken 
vergelijkbaar in gevoeligheid en specificiteit, maar QT-NASBA leverde sneller resultaten met 
gebruik van veel kleinere bloedmonsters. Daarom wordt QT-NASBA beschouwd als 
praktischer dan real-time PCR voor het kwantificeren van P. falciparum parasieten 
[hoofdstuk 3]. 
Tijdens veldstudies zijn voorzieningen om monsters op –70ºC te bewaren vaak beperkt. Om 
het verzamelen van monsters voor QT-NASBA tijdens veldstudies te vereenvoudigen, werd 
een aangepast protocol voor opslag van monsters op -20ºC geëvalueerd [hoofdstuk 4]. Dit 
protocol is gebruikt tijdens studies in Kenia en Burkina Faso en is succesvol gebleken.  
Aanpassing tot real-time detectie van QT-NASBA voor kwantificatie van volgroeide 
gametocyten is beschreven in hoofdstuk 5. In dit hoofdstuk werden gametocyten bestudeerd 
in Keniaanse kinderen met ongecompliceerde, symptomatische P. falciparum infecties, 
tijdens en na behandeling met medicijnen tegen malaria. De QT-NASBA toonde aan dat veel 
kinderen gametocyten hadden, zowel voor als na behandeling met sulphadoxine-
pyrimethamine (SP) of SP+artesunate. Vaak hadden kinderen gametocyten met een lagere 
dichtheid dan de detectielimiet van microscopie. Hoewel combinatietherapie met artesunate, 
in vergelijking met SP monotherapie, resulteerde in een significant minder vaak voorkomen 
en lagere aantallen van gametocyten, werden niet alle gametocyten verwijderd door 
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behandeling. Deze resultaten geven aan dat eerdere schattingen van het reservoir 
gametocyten in de humane populatie waarschijnlijk onderschattingen waren. 
In hoofdstuk 6 werd geconfirmeerd dat kleine aantallen gametocyten veelvuldig voorkomen 
in mensen van alle leeftijden met asymptomatische P. falciparum in Burkina Faso. De data 
tonen aan dat gametocyten minder voorkomen met toenemende leeftijd. Dit zou voor een 
groot deel afhankelijk zou kunnen zijn van de leeftijdsgerelateerde afname van aseksuele 
parasieten. 
Of submicroscopische aantallen gametocyten epidemiologisch van belang zijn werd in het 
laboratorium onderzocht door verdunningsreeksen van P. falciparum gametocyten te voeden 
aan  Anopheles stephensi muggen en vervolgens te kijken of deze geïnfecteerd raakten. Het 
blijkt dat de kans op infectie van een mug toeneemt met het aantal aanwezige gametocyten 
in het bloed. Maar erg lage gametocyten dichtheden kunnen nog steeds muggen infecteren 
en zijn dus belangrijk voor de epidemiologie. Dit is met studies in het veld geconfirmeerd 
[hoofdstuk 7]. 
De voorgaande hoofdstukken benadrukken het belang van submicroscopische aantallen 
gametocyten. In hoofdstuk 8 is het effect van behandeling op malariatransmissie 
beschreven. Drie typen behandelingen die mogelijk SP in Kenia kunnen vervangen werden 
getest op klinische effectiviteit evenals hun effect op transmissie naar Anopheles gambiae 
muggen. Alle drie de geteste typen behandeling hadden een betere klinische effectiviteit 
hadden dan SP. Daarnaast was een vermindering van gametocyten zichtbaar na 
behandeling op basis van artemisine. Dit verminderde niet de fractie kinderen die muggen 
konden infecteren, maar wel het aantal geïnfecteerde muggen. De resultaten uit dit 
proefschrift worden samengevat en besproken in hoofdstuk 9. 
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